Faculty Research & Publications

Department of Pharmacy Practice

Edward M. Bednarczyk, PharmD

Research interests are focused to the application of molecular imaging techniques such as positron emission tomography (PET) to assessing drug effects, including the study of migraine headache where we have looked at treatment as well as induction of headache. We have also had recent work looking at opiate receptors in the human brain using 11C-carfentanil, a radiopharmaceutical that binds to the mu opiate receptor.

The characteristics of positron emitting radio nuclides often make them ideal tracers for measuring drug effects. This includes the labeling drugs with PET radio nuclides such as C-11, or F-18. These nuclides allow for creation of labeled drugs nearly identical to their unlabelled counterparts. We have also used ³workhorse¹ radiopharmaceuticals such as FDG in a variety of settings ranging from measuring the uptake of glucose into white blood cells, to oral administration of this radiopharmaceutical, to application in the assessment of response to drugs in dementia. Other research areas include migraine headache, and neuroreceptor binding studies.

Refereed Journal Articles

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2009)

Kassab, M. Y., Oakhtar, O., Wack, D. S., & Bednarczyk, E. M. (2009). Resting brain glucose uptake in headache free migraineurs. Headache, 49(1), 90-7.

Journal Article, Professional Journal (Published December 2007)

Constantinescu, R. A., McDermott, M. P., DiCenzo, R., deBlieck, E. A., Hyson, H. C., Beal, M. F., Bednarczyk, E. M., Bogdanov, M., Metakis, M. J., Brown, S. E., Lorenzo, B. J., Ravena, B., & Kieburtz, K. (2007). Randomized Study of the Bioavailability of Different Formulations of Coenzyme Q10 (Ubiquinone). J Clin Pharmacol, 47(17), 1580-6.

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2007)

Kassab, M. Y., Majid, A., Farooq, M. U., Azhary, H., Bednarczyk, E. M., Graybeal, D. F., & Johnson, M. (2007). Transcranial Doppler: An Introduction for the Primary Care Physician. JABFM, 20(1), 65-71.

Non-Refereed Journal Articles

Journal Article, Professional Journal (Published October (4th Quarter/Autumn) 2007)

Kassab, M. Y., Majid, A., Bakhtar, O., Farooq, M. U., Patel, K., & Bednarczyk, E. M. (2007). Transcranial Doppler measurements in migraine and nitroglycerin headache. J Headache Pain, 8(5), 289-293.

Other Intellectual Contributions

Abstract (Published July (3rd Quarter/Summer) 2008)

Brazeau, G. A., Havard, P. F., & Bednarczyk, E. M. (2008). Implementation and Assessment of a Formal Junior Faculty Review Process for Enhancing Professional Development.. Chicago, IL: 2008 American Association for Clinical Pharmacy, July 19th - 23rd, 2008.

Terrance J. Bellnier, RPh, MPA

Research interests focused to the areas of pharmacoeconomics, drug efficacy, safety, and side effect management of psychotropics.

Other Intellectual Contributions

Abstract (Published May 2007)

Catanzaro, L. M., Brody, P. M., Fiebelkorn, K. D., Felton, C., Bellnier, T., & Morse, E. D. (2007). Integrated Approach to Community Pharmacy Medication Therapy Management (MTM) and Doctor of Pharmacy Experiential Programs. (3rd ed., vol. 71). AJPE.

Pete Brody, PharmD

Clinical Assistant Professor; Director of Experiential Education

Other Intellectual Contributions

Abstract (Published July (3rd Quarter/Summer) 2007)

Grace, P. M., Slazak, E. M., Fiebelkorn, K. D., & Brody, P. M. (2007). Four separate Measures for Assessing Written and Oral Communication Skills in First Year Pharmacy Students. AACP Annual Meeting.

Abstract (Published May 2007)

Abstract (Published April (2nd Quarter/Spring) 2006)

Grace, P. M., Fiebelkorn, K. D., Brody, P. M., Wahler, R. G., Albanese, N. P., & Burger, D. (2006). Application of Didactic Knowledge in Real World Pharmaceutical Care Situations (3rd ed., vol. 70). AJPE.

Jack Brown, PharmD

Main research interests are the epidemiology, outcomes and economics of bacterial and fungal diseases with interest in using large databases to answer practical questions related to adverse medical events and societal/economic differences in healthcare.

Book Chapters

Book, Chapter in Scholarly Book-Revised (In Preparation; Not Yet Submitted July (3rd Quarter/Summer) 1, 2009)

Brown, J. (2009). Outcomes and Cost Considerations with MRSA Infections. In Weigelt, J. (Ed.), MRSA. Taylor & Francis.

Refereed Journal Articles

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2005)

Brown, J. (2005). Zygomycosis: An emerging fungal infection.

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2004)

Brown, J. (2004). Rethinking the Use of Voriconazole Therapeutic Drug Monitoring in Allogeneic Bone Marrow Transplant Patients.

Journal Article, Professional Journal (Accepted May 2009)

Brown, J., Doloresco, F., & Mylotte, J. M. (2009). Never Events: Not Every Hospital Infection is Preventable. Clinical Infectious Diseases.

Journal Article, Professional Journal (Submitted May 2009)

Brown, J., & Paladino, J. A. (2009). Impact of Rapid MRSA PCR Testing on Mortality and Cost-Effectiveness in Hospitalized Patients with Bacteremia: A Decision Model. Pharmacoeconomics.

Non-Refereed Journal Articles

Journal Article, Professional Journal (Published October (4th Quarter/Autumn) 2006)

Brown, J. (2006). . Shorter Course Antibiotic Therapy for Community Acquired Respiratory Tract Infections: Is Shorter Better?.

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2003)

Brown, J. (2003). Quinupristin-Dalfopristin in Combination with Other Antibiotics for Resistant Gram-Positive Infections.

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2002)

Brown, J. (2002). The Safety of Voriconazole.

Journal Article, Academic Journal (Accepted May 2009)

Brown, J. (2009). Clinical Outcomes of Daptomycin as First Line Therapy Versus Subsequent Therapy..

Journal Article, Academic Journal (Accepted May 2009)

Brown, J. (2009). Clinical Outcomes With daptomycin in First-line Therapy and After Administration of Other Antibiotics for Staphylococcus aureus Infections..

Journal Article, Academic Journal (Accepted May 2009)

Brown, J. (2009). Daptomycin use in Neutropenic Patients with Gram-Positive Bacteremia..

Journal Article, Academic Journal (Accepted May 2009)

Brown, J. (2009). The Pharmacoecomonics of Antifungal Agents in Healthcare Institutions.

Journal Article, Academic Journal (Accepted May 20, 2009)

Brown, J., Doloresco, F., & Mylotte, J. M. (2009). "Never Events" - Not every hospital infection is preventable. Clinical Infectious Disease.

Journal Article, Professional Journal (In Preparation; Not Yet Submitted May 1, 2009)

Prescott, W. A., Doloresco, F., Brown, J., & Paladino, J. A. (2009). Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review.. PharmacoEconomics.

Journal Article, Professional Journal (October (4th Quarter/Autumn) 2006)

Brown, J. (2006). Working together to improve the quality of care for hospitalized community acquired pneumonia patients: The â€œCAPâ€Âï¿½ project at Dartmouth.

Other Intellectual Contributions

Abstract (Published October (4th Quarter/Autumn) 2008)

Brown, J. (2008). Outcomes with Daptomycin for Infective Endocarditis.

Abstract (Published September 2008)

Brown, J. (2008). Decision Analysis to Determine Rapid MRSA PCR Testingâ€™s Impact on Mortality and Quality of Life in Hospitalized Patients with Bacteremia..

Abstract (Published January (1st Quarter/Winter) 2008)

Brown, J. (2008). Daptomycin use in patients with sepsis..

Abstract (Published December 2007)

Brown, J. (2007). Daptomycin (DAP) for the Treatment of Community-Phenotype Methicillin-resistant Staphylococcus aureus (CP-MRSA) Bacteremia.

Abstract (Published December 2007)

Brown, J. (2007). Daptomycin use as outpatient antibiotic therapy.

Abstract (Published October (4th Quarter/Autumn) 2007)

Brown, J. (2007). Daptomycin Outcomes in Patients with Staphylococcus aureus infections by Vancomycin Minimum Inhibitory Concentration (MIC)..

Abstract (Published October (4th Quarter/Autumn) 2007)

Brown, J. (2007). Determinants of Clinical Outcomes in Patients Treated with Daptomycin for Gram-Positive Infections.

Abstract (Published October (4th Quarter/Autumn) 2007)

Brown, J. (2007). Efficacy and Safety of Daptomycin for the Treatment of Community Phenotype Methicillin Resistant Staphylococcus aureus (CP-MRSA) Abscess Requiring Hospitalization..

Abstract (Published October (4th Quarter/Autumn) 2006)

Brown, J. (2006). Efficacy and Safety of Daptomycin for the Treatment of Skin and Skin Structure Infections.

Abstract (Published October (4th Quarter/Autumn) 2006)

Brown, J. (2006). Efficacy and Safety of Daptomycin in Patients Receiving Hemodialysis.

Abstract (Published October (4th Quarter/Autumn) 2006)

Brown, J. (2006). Efficacy and Safety of Daptomycin in Patients Receiving Hemodialysis..

Abstract (Published October (4th Quarter/Autumn) 2006)

Brown, J. (2006). Efficacy and Safety of Daptomycin in Patients Treated for Non-Catheter Related Bacteremia.

Abstract (Published November 2005)

Brown, J. (2005). Evaluation of two antifungal regimens used in the treatment of fever and neutropenia at a tertiary care medical center.

Abstract (Published October (4th Quarter/Autumn) 2005)

Brown, J. (2005). Analysis of Voriconazole for Treatment of C. glabrata Infections at a University Teaching Hospital.

Abstract (Published October (4th Quarter/Autumn) 2003)

Brown, J. (2003). . Evaluation of a new carbapenem, ertapenem, at a large academic medical institution. ASHP Midyear Meeting.

Abstract (Published October (4th Quarter/Autumn) 2003)

Brown, J. (2003). Evaluation of surgical intensive care unit patients with hematogenous disseminated candidiasis; a focus on anti-fungal use and patient outcomes in a university teaching hospital.. ASHP Midyear Meeting.

Abstract (Published October (4th Quarter/Autumn) 2003)

Brown, J. (2003). Linezolid Use in Surgery Patients: A Focus on Thrombocytopenia Incidence and Prevention. Research Forum of the American College of Clinical Pharmacy.

Abstract (Published October (4th Quarter/Autumn) 2002)

Brown, J. (2002). A Multidisciplinary Approach to Improving the Medication Use Process to an Outlying Rehabilitation Facility. ASHP Midyear Meeting.

Abstract (Published October (4th Quarter/Autumn) 2002)

Brown, J. (2002). A Proactive Approach to Preventing Medication Errors.. ASHP Midyear Meeting.

Abstract (Published October (4th Quarter/Autumn) 2002)

Brown, J. (2002). Outcome of Patients Treated with Amphotericin B Lipid Complex (ABLC). Annual Meeting of the Infectious Disease Society of America.

Abstract (Published October (4th Quarter/Autumn) 1, 2000)

Brown, J. (2000). A New Type of Pharmacy Internship Program.

Abstract (October (4th Quarter/Autumn) 2004)

Brown, J. (2004). Reduced Dose Intradermal Influenza Vaccine Is Effective in Reducing Influenza Like Illness.

Linda Catanzaro, PharmD

Director of the Pharmacotherapy Information Center.

Primary research interests are in the fields of drug information and pharmacy informatics. Currently, Dr. Catanzaro is continuing to work in collaboration with other UB SoPPS faculty on projects with the NY State Department of Health (DOH). The projects involve post-marketing drug utilization literature evaluation as well as retrospective drug utilization review (DUR) research for the Office of Medicaid Clinical Drug Review Program. Additional projects for this year will involve the development and tracking of outcomes for the DOH Prescriber Education Program (PEP) as well as the development of a web-based Rapid Response Center for providing drug information in support of the PEP within the Pharmacotherapy Information Center.

Students interested in this type of research will have the opportunity to develop their literature retrieval and evaluation skills and professional writing skills. The DUR research component will provide the opportunity to learn how to analyze insurance claims databases to identify prescribing patterns and opportunities for optimizing appropriate medication use. Participation in the project may also lead to the opportunity for the student to become a published author.

Refereed Journal Articles

Journal Article, Academic Journal (Published September 2008)

McCabe, S. M., Ma, Q., Slish, J., Catanzaro, L. M., Sheth, N., DiCenzo, R., & Morse, E. D. (2008). Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.. Clin Pharmacokinet, 47(3), 153-72.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published March 2008)

McCabe, S. M., Ma, M., Slish, J., Catanzaro, L. M., Sheth, N., DiCenzo, R., & Morse, E. D. (2008). Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment. Clinical Pharmacokinetics, 47(3).

Journal Article, Academic Journal (Published November 2007)

Higgins, N., Zingman, B. S., Reichman, R. C., Fischl, M. A., Gripshover, B., Tooley, K., Boston, N., Forrest, A., Brazeau, D., Catanzaro, L. M., DiFrancesco, R., Lliguicota, F., Ma, Q., Morse, E. D., & Slish, J. (2007). Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. Am J Addict, 16(6), 488-494.

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2007)

Ma, Q., Zingman, B. S., Reichman, R. C., Fischl, M. A., Gripshover, B., Forrest, A., Brazeau, D. A., Boston, N., Catanzaro, L. M., DiFrancesco, R., Morse, E. D., & Slish, J. (2007). Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit, 29(5), 560-565.

Journal Article, Academic Journal (Published February 2006)

Morse, E. D., Catanzaro, L. M., & Acosta, E. P. (2006). Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimize pharmacotherapy. Lancet Infectious Diseases, 6(4), 215-225.

Journal Article, Academic Journal (Submitted August 2009)

Ma, Q., Boston, N., Zingman, B. S., Reichman, R. C., Fischl, M. A., Gripshover, B. M., Slish, J., Catanzaro, L. M., DiFrancesco, R., Forrest, A., & Morse, E. D. (2009). A Pilot Study on Therapeutic Drug Monitoring and Inhibitory Quotients in HIV-Infected Substance Abusers Receiving Protease Inhibitors. Ther Drug Monit.

Other Intellectual Contributions

Abstract (Published May 2008)

Catanzaro, L. M., Nelson, M. M., Lliguicota, F. O., Warrick, J., & Morse, E. D. (2008). Development and Implementation of Web-based HIV Pharmaceutical Care Continuing Education and Certificate Programs (3rd ed., vol. 72). AJPE.

Abstract (Published May 2008)

Coe, H., Catanzaro, L. M., Lliguicota, F. O., & Morse, E. D. (2008). Development of an Academic Pharmacotherapy Information Center Website as a Resource for Community Healthcare Providers (3rd ed., vol. 72). AJPE.

Abstract (Published May 2008)

Felton, C. M., Catanzaro, L. M., & Walsh, T. (2008). Pharmacy Informatics Instruction in Colleges and Schools of Pharmacy (3rd ed., vol. 72). AJPE.

Abstract (Published May 2007)

Abstract (Published May 2006)

Fiebelkorn, K. D., Catanzaro, L. M., Bosinski, A., Brazeau, G. A., Morse, E. D., & Lliguicota, F. (2006). Enhancing Quality in Pharmacy Practice by e-Pharmacotherapy Networks in Asthma, HIV and Poison Prevention (3rd ed., vol. 70). AJPE.

Final Report (Accepted May 2009)

Coe, H., Doloresco, F., & Catanzaro, L. M. (2009). Drug Class Review: Topical Immunomodulators.

Final Report (Submitted May 2009)

Catanzaro, L. M., Doloresco, F., & Coe, H. (2009). Drug Review: Sodium Oxybate.

Position Paper (Submitted May 2009)

Catanzaro, L. M., Doloresco, F., Coe, H., & Fiebelkorn, K. D. (2009). Pharmacists as Immunizers in NYS: Justification for Reimbursement for Pharmacist Vaccinations by NYS Social Services.

Alice Ceacareanu, PharmD/PhD

Research focuses on elucidating the mechanisms of cancer invasion induced or exacerbated by nitric oxide and hallmarks of diabetes type 2. Dr. Ceacareanu’s laboratory also aims at developing predictive screening tools to forecast cancer recurrence and guide antineoplastic therapy to improve treatment outcomes.

Refereed Journal Articles

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2006)

Ceacareanu, A. C., Ceacareanu, B., Zhuang, D., Chang, Y., Ray, R. M., Desai, L., Chapman, K., Waters, C. M., & Hassid, A. A. (2006). Nitric oxide attenuates IGF-I-induced aortic smooth muscle cell motility by decreasing Rac1 activity: essential role of PTP-PEST and p130cas.

Journal Article, Academic Journal (Published March 2006)

Chang, Y., Ceacareanu, B., Zhuang, D., Zhang, C., Pu, Q., Ceacareanu, A. C., & Hassid, A. (2006). Counter-regulatory function of protein tyrosine phosphatase 1B in platelet-derived growth factor- or fibroblast growth factor-induced motility and proliferation of cultured smooth muscle cells and in neointima formation.

Journal Article, Academic Journal (Published March 2006)

Zhuang, D., Ceacareanu, A. C., Lin, Y., Ceacareanu, B., Dixit, M., Chapman, K., Waters, C., rao, G., Hassid, A. (2006). Nitric oxide attenuates insulin- or IGF-I-stimulated aortic smooth muscle cell motility by decreasing H2O2 levels: essential role of cGMP.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2005)

Zhuang, D., Ceacareanu, A. C., Ceacareanu, B., Hassid, A. (2005). Essential role of protein kinase G and decreased cytoplasmic Ca2+ levels in NO-induced inhibition of rat aortic smooth muscle cell motility.

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2004)

Ceacareanu, A. C., Ceacareanu, B., Augustin, O., Rodewald, A., & Szegli, G. (2004). Distribution of D1S80 alleles and their Tsp509I subtypes in Romanian population.

Journal Article, Academic Journal (Published August 12, 2003)

Lin, Y., Ceacareanu, A. C., & Hassid, A. (2003). Nitric oxide-induced inhibition of aortic smooth muscle cell motility: role of PTP-PEST and adaptor proteins p130cas and Crk.

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2002)

Sidorovitch, V., Niculae, A., Kan, N., Ceacareanu, A. C., & Alexandrov, K. (2002). Expression of mammalian Rab Escort protein-1 and -2 in yeast Saccharomyces cerevisiae.

Journal Article, Academic Journal (Published May 12, 2002)

Dursina, B., Thomae, N., Sidorovitch, V., Niculae, A., Iakovenko, A., Rak, A., Albert, S., Ceacareanu, A. C., Ralf, K., Christian, H., Goody, R., Alexandrov, K. (2002). nteraction of yeast Rab geranylgeranyl transferase with its protein and lipid substrates.

Journal Article, In-House Journal (Published August 12, 1999)

Ceacareanu, A. C., Ceacareanu, B., Augustin, O., & Szegli, G. (1999). Parentage analysis for three Romanian families by DNA-fingerprinting.

Journal Article, In-House Journal (Published August 12, 1999)

Ceacareanu, A. C., Ceacareanu, B. (1999). The relevance of paternity analysis in Romanian population using the D1S80 locus.

Other Intellectual Contributions

Abstract (Published July (3rd Quarter/Summer) 2009)

Rickert, M., Drumea, I., Epstein, M., Boateng, H., & Ceacareanu, A. C. (2009). ïƒ˜Impact of repetitive freezing, hemolysis and dilution on cytokine and growth factor profiling by LuminexÂ®.

Abstract (Published May 2008)

Ceacareanu, A. C., Evans, A., Link, A., Morgan, C., & Claiborne, P. (2008). Appropriateness of Antiemetic Premedication in Oncology Patients Receiving Chemotherapy. Athens, GA: Southeastern Residency Conference.

Material Regarding New Courses/Curricula (Submitted August 13, 2009)

Ceacareanu, A. C. (2009). Oncology Elective Course for Third Years Pharmacy Students.

Holly Coe, PharmD

Other Intellectual Contributions

Abstract (Published May 2008)

Final Report (Accepted May 2009)

Coe, H., Doloresco, F., & Catanzaro, L. M. (2009). Drug Class Review: Topical Immunomodulators.

Final Report (Submitted May 2009)

Catanzaro, L. M., Doloresco, F., & Coe, H. (2009). Drug Review: Sodium Oxybate.

Position Paper (Submitted May 2009)

Catanzaro, L. M., Doloresco, F., Coe, H., & Fiebelkorn, K. D. (2009). Pharmacists as Immunizers in NYS: Justification for Reimbursement for Pharmacist Vaccinations by NYS Social Services.

Tammie Lee Demler, PharmD

Psychiatric Pharmacy Practice Residency Program Director, Buffalo Psychiatric Center (NYS Office of Mental Health).

Dr. Demler is the principle investigator on the following research protocols:

Aripiprazole augmention, is an effective approach to psychiatric pharmacotherapy
Safety profile associated with the concomitant use of lorazepam with olanzapine, ziprasidone or haloperidol
Safety profile and efficacy associated with the concomitant use of
clozapine and benzodiazepines.
Clinical outcomes if concomitant use of oseltamivir and clozapine; assessing changes in neutrophil and white blood cell counts
Comorbid illness in a psychiatric state hospital

Future research interests include evaluating efficacy and safety of current psychiatric pharmacotherapeutic interventions, with potential to improve long term success, cost effectiveness and patient adherence.

Fred Doloresco, PharmD, MS

Research interests in cardiology, pharmacoeconomics, outcomes research, and health services research. Specific areas of research include cost-effectiveness of pharmacogenetics and clinical pharmacy services as well as patient preference and decision-making.

Refereed Journal Articles

Journal Article, Academic Journal (Published March 1, 2009)

Doloresco, F., & Vermeulen, L. C. (2009). Global survey of hospital pharmacy practice.. American Journal of Health System Pharmacy, 66(5s), S13-19.

Journal Article, Academic Journal (Published February 1, 2009)

Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Martin, P. K., Blake, S., Matusiak, L., Hunkler, R. J., & Schumock, G. T. (2009). Projecting future drug expenditures--2009.. American Journal of Health-System Pharmacy, 66(3), 237-257.

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2009)

Perez, A., Doloresco, F., Hoffman, J. M., Meek, P. D., Touchette, D. R., Vermeulen, L. C., Schumock, G. T., & ACCP (2009). ACCP: economic evaluations of clinical pharmacy services: 2001-2005.. Pharmacotherapy, 29(1), 128.

Journal Article, Academic Journal (Published February 1, 2008)

Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Grim, P., Hunkler, R. J., Hontz, K. M., & Schumock, G. T. (2008). Projecting future drug expenditures--2009.. American Journal of Health-System Pharmacy, 65(3), 234*253.

Journal Article, Professional Journal (Accepted May 2009)

Brown, J., Doloresco, F., & Mylotte, J. M. (2009). Never Events: Not Every Hospital Infection is Preventable. Clinical Infectious Diseases.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Accepted May 20, 2009)

Brown, J., Doloresco, F., & Mylotte, J. M. (2009). "Never Events" - Not every hospital infection is preventable. Clinical Infectious Disease.

Journal Article, Professional Journal (In Preparation; Not Yet Submitted May 1, 2009)

Prescott, W. A., Doloresco, F., Brown, J., & Paladino, J. A. (2009). Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review.. PharmacoEconomics.

Other Intellectual Contributions

Final Report (Accepted May 2009)

Coe, H., Doloresco, F., & Catanzaro, L. M. (2009). Drug Class Review: Topical Immunomodulators.

Final Report (Submitted May 2009)

Catanzaro, L. M., Doloresco, F., & Coe, H. (2009). Drug Review: Sodium Oxybate.

Position Paper (Submitted May 2009)

Catanzaro, L. M., Doloresco, F., Coe, H., & Fiebelkorn, K. D. (2009). Pharmacists as Immunizers in NYS: Justification for Reimbursement for Pharmacist Vaccinations by NYS Social Services.

Karl Fiebelkorn, R.Ph., MBA

Main interests areas:

Research and application of the laws, rules and regulations, both federal and state affecting pharmacy practice issues in NYS. These include current legislative issues affecting the expansion of pharmacists' responsibility in patient care along with the application of business models for improving the corresponding revenue streams that any legal changes may create.
Studying areas to improve the recognition, and reporting of medication errors and systems for improvement of practice sites for enhancement of patient outcomes. A New York State Department of Health pilot study involving medication errors and prescriptions is currently underway.
Management of adult Asthma in the ambulatory/community settings. I am a board certified educator in asthma and am working with the Western New York Asthma Coalition.
Business plan modeling for area pharmacy related businesses to improve efficiency and profitability.

Other Intellectual Contributions

Abstract (Published July (3rd Quarter/Summer) 2007)

Abstract (Published May 2007)

Fiebelkorn, K. D., Grace, P., Renzi, S., Brazeau, G. A. (2007). Correlation of Key Issues Utilizing Curricular Mapping with Outcomes Surveys and Senior Exit Interviews (3rd ed., vol. 71). AJPE.

Abstract (Published May 2007)

Abstract (Published May 2006)

Abstract (Published April (2nd Quarter/Spring) 2006)

Abstract (Published January (1st Quarter/Winter) 2002)

Brazeau, G. A., Haas, C., Fung, H., Fiebelkorn, K. D. (2002). Cultivating Future Clinical and Pharmaceutical Academic Research Leaders in PharmD Students (ed., vol. 66). AJPE.

Abstract (Published July (3rd Quarter/Summer) 1998)

Brazeau, G. A., Haas, C., Fung, H., Fiebelkorn, K. D. (1998). Preparing Students in Professional Practice Lab for the Professional Experience Program (4th ed., vol. 62). AJPE.

Position Paper (Submitted May 2009)

Fiebelkorn, K. D., & Park, S. (2009). Pharmacist Citizenship in NYS: A time for Change.

Position Paper (Submitted May 2009)

Catanzaro, L. M., Doloresco, F., Coe, H., & Fiebelkorn, K. D. (2009). Pharmacists as Immunizers in NYS: Justification for Reimbursement for Pharmacist Vaccinations by NYS Social Services.

Study Guide (Submitted November 2008)

Bruce, S. A., & Fiebelkorn, K. D. (2008). Legal Prescribing in New York State. The Nurse Practitioner Association of New York State.

Alan Forrest, PharmD

Main research interests focus on work with research-track students on PK/PD analysis projects. These could include: PK and or PD parameter estimation, approaches to optimal study design, development and validation of adaptive feedback control algorithms (use of PK and PD principles to individually-optimize dosing regimens).

Refereed Journal Articles

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2009)

Bulitta, J. B., Ly, N. S., Yang, J. C., Forrest, A., Jusko, W. J., & Tsuji, B. T. (2009). Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrob. Ag. Chemother., 53(1), 46-56.

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2008)

Ma, Q., Forrest, A., Rosenkranz, S. L., Para, M. F., Yarasheski, K. E., Reichman, R. C., & Morse, E. D. (2008). Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos, 29(2), 91-101.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2008)

von Eiff, C., Kelchlin, P. A., Forrest, A., Smith, P., & Tsuji, B. T. (2008). Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother, 52(4), 1533-1537.

Journal Article, Professional Journal (Published March 2008)

Gengo, F. M., Robson, M., Gengo, M. F., Forrest, A., Rainka, M. M., Hourihane, J. M., & Bates, V. (2008). Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol, 48(3), 335-343.

Journal Article, Academic Journal (Published December 2007)

Yang, J. C., Forrest, A., & Tsuji, B. T. (2007). Optimizing use of quinolones in the critically ill. Semin Respir Crit Care Med, 28(6), 586-595.

Journal Article, Academic Journal (Published September 2007)

Ma, Q., Brazeau, D. A., Forrest, A., & Morse, E. D. (2007). Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics, 8(9), 1169-78.

Journal Article, Academic Journal (Published March 2007)

Ma, Q., Brazeau, D. A., Zingman, B. S., Reichman, R. C., Fischl, M. A., Gripshover, B. M., Venuto, C. S., Slish, J., DiFrancesco, R., Forrest, A., & Morse, E. D. (2007). Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics, 8(3), 227-35.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2008)

Moise, P. A., Smyth, D. S., El-Fawal, N., Robinson, D. A., Holden, P. N., Sakoulas, G., & Forrest, A. (2008). Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother, 61(1), 85-90.

Journal Article, Academic Journal (Published December 2007)

Ambrose, P. G., Craig, W. A., Rubino, C. M., Bhavnani, S., Drusano, G. L., Heine, H. S., & Forrest, A. (2007). Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrob Agents Chemother, 51(12), 4351-4355.

Journal Article, Academic Journal (Published November 2007)

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2007)

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 23, 2007)

Moise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007). Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother, 51(7), 2582-6.

Journal Article, Academic Journal (Submitted August 2009)

Journal Article, Academic Journal (Working Paper August 2009)

Ma, Q., Venuto, C. S., Brazeau, D. A., Zingman, B. S., Reichman, R. C., Forrest, A., & Morse, E. D. (2009). Effects of CYP2B6 single nucleotide polymorphisms and substance abuse on efavirenz pharmacokinetics. Clin Pharmacol Ther.

Journal Article, Academic Journal (Working Paper August 2009)

Ma, Q., Zingman, B. S., Forrest, A., & Morse, E. D. (2009). PROTEASE INHIBITOR AND EFAVIRENZ PLASMA CONCENTRATION MONITORING IN HIV-INFECTED SUBSTANCE USERS. J Acquir Immune Defic Syndr.

Journal Article, Academic Journal (Working Paper August 2009)

Ma, Q., Acheampong, F. A., Brazeau, D. A., Zingman, B. S., Forrest, A., & Morse, E. D. (2009). Relationship between CYP3A5 Single Nucleotide Polymorphisms (SNPs) and Protease Inhibitor (PI) Trough Concentrations in HIV+ Patients during Therapeutic Drug Monitoring. Ther Drug Monit.

Other Intellectual Contributions

Abstract (Published April (2nd Quarter/Spring) 2009)

Gengo, F. M., Iyer, V. S., Mathew, R., Michael, G., Michelle, R. M., & Forrest, A. (2009). Effects of Naproxin on the Time Course of Aspirin Induced Inhibition of Platelet Aggregation. New York NY: 110th Annual Meeting American Society of Clinical Pharmacology and Therapeutics.

Abstract (Published February 2009)

Lubin, R., Tam, P. Y., Brazeau, D. A., Forrest, A., Colombo, D., Liu, Z., & Havard, P. F. (2009). The Relationship of ABCB1 Gene Expression and the C3435T and G2677T Polymorphisms between Maternal and Fetal Peripheral Blood Mononuclear Cells (PBMCs) [Abstract 931]. Montreal: 2009 16th Conference Retrovirus Opporunistic Inefections Meeting.

Abstract (Published July (3rd Quarter/Summer) 2007)

Okusanya, O. O., Dole, K., Zack, J., Forrest, A., Gundroo, A. A., Lecca, N., Venuto, R. C., & Tornatore-Morse, K. M. (2007). Population Pharmacokinetic Model of Mycophenolic Acid and its Metabolite-Mycophenolic Acid Glucuronide in Long Term Renal Transplant Patients using Monte CArlo Parametric Expectation Maximization (2nd ed., vol. 81). Clin. Pharmacol.Ther..

Manuscript (Published July (3rd Quarter/Summer) 2007)

Moise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007). Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. (7th ed., vol. 51, pp. 2582-6). Washington DC: Antimicrob Agents Chemother.

Journal (Published April (2nd Quarter/Spring) 12, 2007)

Moise-Broder, P., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007). Vancomycin in vitro Bacteridical Activity and it's Relationship to Efficacy in clearance on Methicillin-Resistant Staph aureus bacteremia. Antimicrob Agents Chemother, 2007, 2582â€“2586..

Fran Gengo, PharmD

Research conducted at the Neurologic Institute focused to neuropharmacology and a clinical research interest in PK-PD of neuroactive compounds.

Ethanol Pharmacology: Conducts clinical studies to examine the pharmacokinetic and pharmacodynamic models of ethanol pharmacologic effects.
Headache: Clinical management models for headache pharmacotherapy.
Alzheimer’s: Clinical management models for Alzheimer’s pharmacotherapy.

Book Chapters

Book, Chapter in Textbook-Revised (Published January (1st Quarter/Winter) 2008)

Gengo, F. M. (2008). Pharmacologic principles and treating neurologic disease. In Neurology in clinical practice (vol. 1, pp. 859-898). Philadelphia Pa: Butterworth Heinemann Elsevier.

Refereed Journal Articles

Journal Article, Professional Journal (Published March 2008)

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2008)

Gengo, F. M., Rubin, L., Robson, M., Rainka, M., Mager, D. E., & Bates, V. (2008). Effects of Ibuprofen on the Magnitude and Duration of Aspirinâ€˜s Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis. J Clin Pharmacol, 48(1), 117-122.

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2008)

Hong, Y., Gengo, F. M., Rainka, M. N., Bates, V. E., & Mager, D. E. (2008). Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet, 47(2), 129-137.

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2007)

Gengo, F. M. (2007). Effects of Ibuprofen on Sleep Quality as Measured Using Polysomnography and Subjective Measures in Healthy Volunteers. Clinical Therapeutics 2007 Vol 28 No 11 1820-1826, 28(11), 1820-1826.

Other Intellectual Contributions

Abstract (Published April (2nd Quarter/Spring) 2009)

Gengo, F. M., Michelle, R. M., Mathew, R., Michael, G. F., Joseph, H. M., & Vernice, B. (2009). Response to Increased Aspirin Dose in Patients whose Platelets were Non Responsive to Low Dose Aspirin (vol. 40, pp. e105-2276). Stroke, Apr 2009; 40: e105 - e276.

Patty Havard, PharmD

Research focuses on three areas: 1) characterization of drug transporter proteins and evaluation of protein function on the intracellular disposition of HIV-1 PIs in peripheral blood mononuclear cells between the maternal and fetal compartments; 2) evaluation of maternal, pregnancy and newborn outcomes following antepartum chemoprophylaxis in HIV-infected women; 2) pharmacokinetics/pharmacodynamics of ART in pregnancy; and 3) HIV-1 protease inhibitors induced placental cell injury; and 4)

Strong efforts are made to characterize a variety of drug efflux transporter proteins and its function in the intracellular disposition of HIV-1 PIs in PBMCs between the mother and baby at the time of delivery.

Data on the safety of ART use and obstetrical management of ART-associated side effects during pregnancy remain limited. A database to monitor maternal, pregnancy, newborn outcomes study following antepartum ART chemoprophylaxis to reduce perinatal HIV-1 transmission has been established for patients referred to the HIV High Risk Pregnancy Program at the Ohio State University. Students will have opportunities to establish and maintain an outcomes database for HIV-infected pregnant women referred to the Erie County Medical Center (ECMC). Efforts will be made to merge the outcomes database between ECMC and OSU. The inter-university collaboration between OSU and the University at Buffalo (UB) will increase the outcomes data to better assess the efficacy and safety of ART use during pregnancy.

We recently reported a significant increase in the placental weight, placenta: newborn weight ratio, surface area, and thickness in dams despite a lack of difference in maternal plasma glucose. A similar trend was observed among HIV (+) women on a PI-containing antepartum regimen. These clinical findings support those observed in the experimental rat model and suggest a PI effect on the placenta that is glucose-independent. We are directing our research efforts on exploring PI-induced placental endothelial cell injury as a possible mechanism.

Qing Ma, PharmD

Research interests areas:

Pharmacogenomics of antiretrovirals and lipid-lowering agents in patients with HIV infection (collaboration with Daniel Brazeau)
Mechanisms of drug-drug interactions in patients with HIV infection (collaboration with Gene Morse)
Development of novel analytical methods for antiretrovirals and interacting agents (collaboration with Robin DiFrancesco and Jill Hochreitter)
Incorporating pharmacokinetics, pharmacodynamics and pharmacogenomics in studying the clinical effects of drugs and in monitoring drug therapy; applying Bayesian methods and population approaches to the analysis of antiretrovirals (collaboration with Alan Forrest)

Refereed Journal Articles

Journal Article, Academic Journal (Published August 2009)

Lakhman, S. S., Ma, Q., & Morse, E. D. (2009). Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics, 10(8), 1323-1339.

Journal Article, Academic Journal (Published September 2008)

Cheang, K. I., & Ma, Q. (2008). Research in women and special populations. Pharmacotherapy, 28, 93e-113e.

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2008)

Journal Article, Academic Journal (Published September 2007)

Ma, Q., Brazeau, D. A., Forrest, A., & Morse, E. D. (2007). Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics, 8(9), 1169-78.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2007)

McCabe, S. M., Smith, P. F., Ma, Q., & Morse, E. D. (2007). Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol, 3(2), 197-207.

Journal Article, Academic Journal (Published March 2007)

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published December 2007)

McCance-Katz, E. F., Moody, D. E., Ma, Q., DiFrancesco, R., Friedland, G., Pade, P., Rainey, P. M., & Morse, E. D. (2007). Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend, 91(2-3), 269-278.

Journal Article, Academic Journal (Published November 2007)

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2007)

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2007)

Maponga, C., Ma, Q., Slish, J., & Morse, E. D. (2007). HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Top HIV Med, 15(3).

Journal Article, Academic Journal (Submitted August 2009)

Journal Article, Academic Journal (Working Paper August 2009)

Ma, Q., Zingman, B. S., Forrest, A., & Morse, E. D. (2009). PROTEASE INHIBITOR AND EFAVIRENZ PLASMA CONCENTRATION MONITORING IN HIV-INFECTED SUBSTANCE USERS. J Acquir Immune Defic Syndr.

Journal Article, Academic Journal (Working Paper August 2009)

Charles Maponga, PharmD

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2007)

Maponga, C., Ma, Q., Slish, J., & Morse, E. D. (2007). HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Top HIV Med, 15(3).

Scott Monte, PharmD

Refereed Journal Articles

Journal Article, Professional Journal (Published 2009)

Monte, S. V., Slazak, E. M., Albanese, N. P., Adelman, M., Rao, G., & Paladino, J. A. (2009). Clinical and Economic Impact of a Diabetes Clinical Pharmacy Service Program in a University and Primary Care-Based Collaboration Model. J Am Pharm Assoc, 49, 200-208.

Journal Article, Professional Journal (Published September 2008)

Monte, S. V., Prescott, W. A., Johnson, K. K., Lori, K., & Paladino, J. A. (2008). Safety of Ceftriaxone at the Extremes of Age. Expert Opinion on Drug Safety, 7(5), 515-23.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Albanese, N. P., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections. American Journal of Managed Care, 14, 190-196.

Non-Refereed Journal Articles

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2009)

File, T. M., Monte, S. V., & Schentag, J. J. (2009). A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.. Int J Antimicrob Agents, 33(1), 58-64.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Paolini, N. M., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections. Am J Manag Care, 14(4), 190-196.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Paolini, N. M., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections.. Am J Manag Care, 14(4), 190-6.

Other Intellectual Contributions

Abstract (Published December 2008)

Herges, J., Monte, S. V., Slazak, E. M., Albanese, N. P., & Paladino, J. A. (2008). Comparison of Pharmacist-Physician Collaborative and Physician Only Management of Type 2 Diabetes Mellitus in the Primary Care Setting. ASHP Midyear Clinical Meeting.

Abstract (Published December 2007)

Mac Evoy, M. S., Slazak, E. M., Paladino, J. A., & Monte, S. V. (2007). Evaluation of atorvastatin to simvastatin conversion in a primary care physician group and the impact on quality of care. ASHP Midyear Clinical Meeting.

Abstract (Published October (4th Quarter/Autumn) 2007)

Paladino, J. A., Monte, S. V., Albanese, N. P., Slazak, E. M., & Schentag, J. J. (2007). Costs of Outpatients Lower Respiratory Tract Infection in an Adult Managed Care Population. ICAAC.

Abstract (Published December 2006)

Monte, S. V., Paolini, N., Slazak, E. M., & Paladino, J. A. (2006). Cost of Outpatient Lower Respiratory Tract Infection in an Adult Primary Care Population. ASHP Midyear Clinical Meeting.

Abstract (Working Paper October (4th Quarter/Autumn) 2008)

McCauley, P. E., Monte, S. V., Albanese, N. P., & Paladino, J. A. (2008). Characterization of Type 2 Diabetes Pharmacologic Therapies Over Time in a Primary Care Setting. ASHP Midyear Clinical Meeting, Poster Presented.

Gene D. Morse, PharmD

Associate Director of the UB NYS Center of Excellence for Bioinformatics and Life Sciences.

Dr. Morse leads the UB AIDS Clinical Trials Group Pharmacology Specialty Laboratory and the UB HIV/AIDS Clinical Pharmacology Quality Assurance and Quality Control Program that are supported by NIH grants from the National Institute of Allergy and Infectious Diseases and the National Institute on Drug Abuse. Dr. Morse directs the HIV Treatment Education Program at the Erie County Medical Center in Buffalo and the International Center for HIV/AIDS Pharmacotherapy Research and Training Program (ICHAPRT). ICHAPRT provided research and education for international students and faculty with an interest in HIV/AIDS treatment. Information on these programs is available at www.hiv.buffalo.edu.

Dr. Morse, along with other SoPPS faculty, is developing the Translational Pharmacology Research Core (TPRC) program in the New York State Center of Excellence in Bioinformatics and Life Sciences. The TPRC has four components including: 1) a Translational Pharmacology Core Facility for Bioanalysis and Drug Development, 2) a Bioinformatics and Medication Management Research Network, 3) a Translational Pharmacogenomics program and 4) a Translational Pharmacotherapy Research Center. The TPRC has been designated by the Patient Safety Center of the NYS Department of Health as the Coordinating Center for a statewide ePrescribing initiative. These research components have common areas of interest with the other research cores and SoPPS faculty research initiatives. The TPRC is actively participating in the UB 2020 planning process with other faculty and clinician scientists located on the Buffalo Niagara Medical Campus to develop interdisciplinary programs within the UB 2020 Health and Wellness Across the Lifespan Strategic Strength.

Book Chapters

Book, Chapter in Scholarly Book-New (Published October (4th Quarter/Autumn) 2008)

Sawyer, J. R., Acosta, E. P., Morse, E. D. (2008). Raltegravir. In Shafer, R. W., Swindells, S., Singh, N., Sun, H. (Eds.), HIV Clinical Manual.

Book, Chapter in Scholarly Book-New (Accepted January (1st Quarter/Winter) 2009)

Morse, E. D., Havard, P. F., Crutchely, R., Brilliant, A. (2009). Maraviroc. In: Antimicrobial Therapy and Vaccines: Volume II: Antimicrobial Agents, 3rd Edition.. In Yu, V., Edwards, G., McKinnon, P., Peloquin, C., Morse, E. D. (Eds.), Antimicrobial Therapy and Vaccines: Volume II: Antimicrobial Agents, 3rd Edition. (ed., vol. II). Pittsburg, PA: Technologies, LLC.

Refereed Journal Articles

Journal Article, Academic Journal (Published August 2009)

Lakhman, S. S., Ma, Q., & Morse, E. D. (2009). Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics, 10(8), 1323-1339.

Journal Article, Academic Journal (Published September 2008)

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2008)

Journal Article, Academic Journal (Published September 2007)

Ma, Q., Brazeau, D. A., Forrest, A., & Morse, E. D. (2007). Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics, 8(9), 1169-78.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2007)

McCabe, S. M., Smith, P. F., Ma, Q., & Morse, E. D. (2007). Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol, 3(2), 197-207.

Journal Article, Academic Journal (Published March 2007)

Journal Article, Professional Journal (Accepted April (2nd Quarter/Spring) 2009)

Dunkle, M. N., Hochreister, J., DiFrancesco, R., Morse, E. D., & Colon, L. A. (2009). Separation of Phosphorylated Nucleoside Reverse Transcriptase Inhibitors by Capillary electrophoresis. To appear in Microchemical Journal.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published May 1, 2009)

(2009). A randomized trial of therapeutic drug.

Journal Article, Academic Journal (Published May 1, 2009)

Morse, E. D. (2009). Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy..

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 28, 2009)

Demeter, L., Jiang, H., Mukherjee, L., Morse, E. D., DiFrancesco, R., DiCenzo, R., Dykes, C., Sista, P., Bacheler, L., Klingman, K., Rinehart, A., & Albrecht, M. (2009). A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS, 23(3), 357-368.

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 28, 2009)

Demeter, L., Jiang, H., Mukherjee, L., Morse, E. D., DiFrancesco, R., DiCenzo, R., Dykes, C., Sista, P., Bacheler, L., Klingman, K., Rinehart, A. (2009). A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS, 3, 357-368.

Journal Article, Academic Journal (Published March 2008)

Journal Article, Academic Journal (Published December 2007)

Journal Article, Academic Journal (Published November 2007)

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2007)

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2007)

Maponga, C., Ma, Q., Slish, J., & Morse, E. D. (2007). HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Top HIV Med, 15(3).

Journal Article, Academic Journal (Published February 2006)

Journal Article, Academic Journal (Submitted August 2009)

Journal Article, Academic Journal (Working Paper August 2009)

Ma, Q., Zingman, B. S., Forrest, A., & Morse, E. D. (2009). PROTEASE INHIBITOR AND EFAVIRENZ PLASMA CONCENTRATION MONITORING IN HIV-INFECTED SUBSTANCE USERS. J Acquir Immune Defic Syndr.

Journal Article, Academic Journal (Working Paper August 2009)

Other Intellectual Contributions

Abstract (Published May 2008)

Abstract (Published May 2007)

Abstract (Published April (2nd Quarter/Spring) 2007)

Slazak, E. M., Albanese, N. P., Wrobel, M., Monte, S. V., Orlick, A. E., Ambres, C. A., & Morse, E. D. (2007). MedSense, and Academic Medication Management Program in a Primary Care Group Practice. AACP.

Journal (Published February 8, 2007)

Cohen, C. J., Colson, A. E., Sheble-Hall, A. G., McLaughlin, K. A., & Morse, E. D. (2007). Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clinical Trials(1), 19-23.

Abstract (Published July (3rd Quarter/Summer) 2006)

Albanese, N. P., Coe, H. V., Snow, I. I., Notaro, J. C., & Morse, E. D. (2006). Pharmacotherapy Management Program: Development of Initial Outcomes in a Multi-Specialty Physician's Group. AACP.

Abstract (Published May 2006)

Abstract (Published October (4th Quarter/Autumn) 2005)

Slazak, E. M., Paolini, N. M., Broffman, G., & Morse, E. D. (2005). Evaluation of Patient-Centered Pharmacotherapy Management in a Managed Care Organization. ACCP Annual Meeting.

Nicholas B. Norgard, PharmD BCPS

Research interests lie in the area of cardiovascular disease with a specific focus on antiplatelet pharmacology and platelet function monitoring. There is increasing interest in the use of platelet function tests to monitor the effects of antiplatelet drugs, with the goal of guiding therapy to the optimal dose for the prevention and treatment of thrombosis while minimizing hemorrhagic complications. In addition, the cardiovascular risk of several non-cardiac drugs has recently come into question. Dr. Norgard’s research incorporates the coated-platelet assay, an innovative approach for analyzing platelet function and the thrombotic potential of a drug.

Research goal is to provide critical insight into the coated-platelet role in thrombotic occlusions that may ultimately be utilized to design effective strategies for prevention and treatment of atherothrombotic diseases and to establish the coated-platelet assay as a marker of thrombotic capability that can be used to monitor medication efficacy and safety.

Book Chapters

Book, Chapter in Textbook-New (Accepted May 1, 2009)

Norgard, N. B. (2009). Cardiology - In Depth Look: Cardiovascular Disease. In Development of Therapeutic Agents. John Wiley and Sons.

Refereed Journal Articles

Journal Article, Academic Journal (Published August 1, 2009)

Norgard, N. B. (2009). Cangrelor: a novel P2Y12 receptor antagonist.. Expert Opinion on Investigational Drugs, 18(8), 1219-30.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 1, 2009)

Norgard, N. B. (2009). Cangrelor attenuates coated-platelet formation. Clinical and Applied Thrombosis and Hemostasis, 15(2), 177-182.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 1, 2009)

Norgard, N. B. (2009). Drug Interaction between clopidogrel and proton pump inhibitors. Annals of Pharmacotherapy.

Journal Article, Academic Journal (Published December 1, 2008)

Norgard, N. B. (2008). Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization. Journal of Cardiovascular Pharmacology, 52(6), 563-9.

Journal Article, Academic Journal (Published November 1, 2008)

Norgard, N. B. (2008). Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists.. Recent patents on cardiovascular drug discovery, 3(3), 194-200.

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 1, 2008)

Norgard, N. B. (2008). Pharmacotherapy of heart failure: beyond ace-inhibitors and beta-blockers. Pharmacotherapy, 28(7), 920-31.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Accepted September 2009)

Norgard, N. B., & Abu-Fadel, M. (2009). Comparative analysis of antiplatelet agents in patients with acute coronary syndrome undergoing percutaneous coronary intervention. To appear in Vascular Health and Risk Management.

Journal Article, Academic Journal (In Preparation; Not Yet Submitted May 12, 2009)

(2009). Comparative analysis of antiplatelet agents in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vascular Health and Risk Management.

Other Intellectual Contributions

Abstract (Published April (2nd Quarter/Spring) 15, 2009)

Norgard, N. B. (2009). Rebound in thrombotic potential while on clopidogrel. American College of Clinical Pharmacists spring meeting.

Joseph Paladino, PharmD

Fellowship Director, Pharmacoeconomics.

Research interest areas:

Pharmacoeconomic evaluation of antimicrobial therapy for pneumonia and geriatric therapy.
Clinical trails of developmental antibacterial agents.

Refereed Journal Articles

Journal Article, Professional Journal (Published 2009)

Journal Article, Professional Journal (Published September 2008)

Monte, S. V., Prescott, W. A., Johnson, K. K., Lori, K., & Paladino, J. A. (2008). Safety of Ceftriaxone at the Extremes of Age. Expert Opinion on Drug Safety, 7(5), 515-23.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Albanese, N. P., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections. American Journal of Managed Care, 14, 190-196.

Journal Article, Professional Journal (Submitted May 2009)

Brown, J., & Paladino, J. A. (2009). Impact of Rapid MRSA PCR Testing on Mortality and Cost-Effectiveness in Hospitalized Patients with Bacteremia: A Decision Model. Pharmacoeconomics.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published June 2008)

Gilliland-Johnson, K. K., Adelman, M. H., Cohn, S. M., & Paladino, J. A. (2008). Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections. Surg Infect (Larchmt), 9(3), 325-333.

Journal Article, Professional Journal (Published June 15, 2008)

Paladino, J. A., Sunderlin, J. E., Singer, M. E., Adelman, M. H., & Schentag, J. J. (2008). Am J Health Syst Pharm, 65(12), 1154-9.

Journal Article, Professional Journal (Published June 15, 2008)

Paladino, J. A. (2008). of extended-spectrum beta-lactams on gram-negative bacterial resistance. Am J Health Syst Pharm, 65(12), 1154-9.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Paolini, N. M., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections. Am J Manag Care, 14(4), 190-196.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Paolini, N. M., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections.. Am J Manag Care, 14(4), 190-6.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008). Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents, 31(4), 345-51.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Journal Article, Professional Journal (Published February 15, 2008)

Paladino, J. A., & Schentag, J. J. (2008). The economics of Clostridium difficile-associated disease for providers and payers. Clin Infect Dis, 46(4), 505-6.

Journal Article, Professional Journal (Published October (4th Quarter/Autumn) 19, 2007)

Iannini, P. B., Paladino, J. A., Lavin, B., Singer, M. E., Schentag, J. J. (2007). A case series of macrolide treatment failures in community acquired pneumonia. J Chemother., 19(5), 536-45.

Journal Article, Professional Journal (Published August 1, 2007)

Paladino, J. A., Sunderlin, J. L., Adelman, M. H., Singer, M. E., & Schentag, J. J. (2007). Observations on vancomycin use in U.S. hospitals. Am J Health Syst Pharm, 64(15), 1633-41.

Journal Article, Professional Journal (Published August 1, 2007)

Paladino, J. A., Sunderlin, J. L., Adelman, M. H., Singer, M. E., & Schentag, J. J. (2007). Observations on vancomycin use in U.S. hospitals. Am J Health Syst Pharm.. Observations on vancomycin use in U.S. hospitals, 64(15), 1633-41.

Journal Article, Professional Journal (Published May 2007)

Paladino, J. A., Eubanks, D. A., Adelman, M. H., & Schentag, J. J. (2007). Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia. J Am Geriatr Soc, 55(5), 651-7.

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2007)

Paladino, J. A., Adelman, M. H., Schentag, J. J., & Iannini, P. B. (2007). Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.. Pharmacoeconomics, 25(8), 677-83.

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2007)

Paladino, J. A., Adelman, M. H., Schentag, J. J., & Iannini, P. B. (2007). Direct costs in patients hospitalized with community-acquired pneumonia after non response to outpatient treatment with macrolide antibacterials in the US. PharmacoEconomics, 25, 677-683.

Journal Article, Professional Journal (In Preparation; Not Yet Submitted May 1, 2009)

Prescott, W. A., Doloresco, F., Brown, J., & Paladino, J. A. (2009). Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review.. PharmacoEconomics.

Other Intellectual Contributions

Abstract (Published December 2008)

Manuscript (Published April (2nd Quarter/Spring) 2008)

Paladino, J. A., & Schentag, J. J. (2008). The economics of Clostridium difficile-associated disease for providers and payers. (4th ed., vol. 46, pp. 505-6). Chicago, IL: Clin Infect Dis.

Comment (Published February 2008)

Paladino, J. A., & Schentag, J. J. (2008). The economics of Clostridium difficile-associated disease for providers and payers (4th ed., vol. 46, pp. 505-506). Clin Infect Dis.

Abstract (Published December 2007)

Abstract (Published October (4th Quarter/Autumn) 2007)

Paladino, J. A., Monte, S. V., Albanese, N. P., Slazak, E. M., & Schentag, J. J. (2007). Costs of Outpatients Lower Respiratory Tract Infection in an Adult Managed Care Population. ICAAC.

Manuscript (Published August 2007)

Paladino, J. A., Adelman, M. H., Schentag, J. J., & Iannini, P. B. (2007). Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US. (8th ed., vol. 28, pp. 677-83). Yardley, PA: Pharmacoeconomics..

Manuscript (Published August 1, 2007)

Paladino, J. A., Sunderlin, J. L., Adelman, M. H., Singer, M. E., & Schentag, J. J. (2007). Observations on vancomycin use in U.S. hospitals. (vol. 64, pp. 1633-1641). Am J Health Syst Pharm.

Manuscript (Published May 2007)

Paladino, J. A., Eubanks, D. A., Adelman, M. H., & Schentag, J. J. (2007). Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia (5th ed., vol. 55, pp. 651-657). J Am Geriatr Soc.

Abstract (Published December 2006)

Monte, S. V., Paolini, N., Slazak, E. M., & Paladino, J. A. (2006). Cost of Outpatient Lower Respiratory Tract Infection in an Adult Primary Care Population. ASHP Midyear Clinical Meeting.

Abstract (In Preparation; Not Yet Submitted October (4th Quarter/Autumn) 2005)

Mark, W., Slazak, E. M., Albanese, N. P., & Paladino, J. A. (2005). Economic Analysis of Montelukast Plus Short-acting Beta-2-agonist verses short-acting beta-2-agonist alone in a pediatric asthma population. ASHP Clinical Midyear Meeting.

Abstract (Working Paper October (4th Quarter/Autumn) 2008)

Nicole Paolini, PharmD

Research interest areas:

Management of diabetes in an ambulatory care setting.
Innovative approaches to the pharmacotherapy of chronic diseases.
Alternative practice models focused on patient education and medication adherence

Book Chapters

Book, Chapter in Textbook-Revised (Published)

Albanese, N. P., Coe, H. Systemic Lupus Erythmatosus. In Schwinghammer, T., Koehler, J. M. (Eds.), Pharmacotherapy Casebook: A Patient-Focused Approach (ed.). New York: McGraw-Hill, 2008:.

Book, Chapter in Textbook-Revised (Published)

Small, R. E., Albanese, N. P. Systemic Lupus Erythmatosus. In Schwinghammer, T., Koehler, J. M. (Eds.), Pharmacotherapy Casebook: A Patient-Focused Approach (ed.). Connecticut: Appleton and Lange.

Book, Chapter in Textbook-New (Accepted)

Albanese, N. P. Hypothyroid: "Dairy" Consequences. In Goode, K. (Ed.), Case Studies: Patient Education and Medication Management for Community Pharmacy Practice. APhA.

Refereed Journal Articles

Journal Article, Professional Journal (Published 2009)

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Albanese, N. P., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections. American Journal of Managed Care, 14, 190-196.

Other Intellectual Contributions

Abstract (Published)

Albanese, N. P. Assessing if Patients with Diabetes are Meeting the American Diabetes Association REcommendations with their Care in Community Practice. Diabetes in Control.

Position Paper (Published)

Albanese, N. P., & Rouse, M. J. Scope of Contemporary Pharmacy Practice: Roles, Responsibilities, and Functions of Pharmaicsts and Pharmacy Technicians. Washington, DC: Council on Credentialing.

Abstract (Published December 2008)

Abstract (Published October (4th Quarter/Autumn) 2007)

Paladino, J. A., Monte, S. V., Albanese, N. P., Slazak, E. M., & Schentag, J. J. (2007). Costs of Outpatients Lower Respiratory Tract Infection in an Adult Managed Care Population. ICAAC.

Magazine/Trade Publication (Published October (4th Quarter/Autumn) 2007)

Albanese, N. P. (2007). Five years post residency training: Was it worth it? (vol. 18). September/October 2007: Student Pharmacist, APhA.

Abstract (Published July (3rd Quarter/Summer) 2007)

Albanese, N. P., & Wahler, R. G. (2007). Practical Application of the CAPE Educational Outcomes within the Pharmaceutical Care Course Sequence at the University at Buffalo. AACP.

Abstract (Published April (2nd Quarter/Spring) 2007)

Abstract (Published July (3rd Quarter/Summer) 2006)

Albanese, N. P., Coe, H. V., Snow, I. I., Notaro, J. C., & Morse, E. D. (2006). Pharmacotherapy Management Program: Development of Initial Outcomes in a Multi-Specialty Physician's Group. AACP.

Abstract (Published April (2nd Quarter/Spring) 2006)

Magazine/Trade Publication (Published 2003)

Albanese, N. P. (2003). The Pharmacist's Role in Management of Rheumatoid Arthritis (pp. 69-75). August 2003: Pharmacy Practice News.

Magazine/Trade Publication (Published July (3rd Quarter/Summer) 2003)

Albanese, N. P. (2003). Make sure your young patients do not scratch their way back-to-school. 2003: Student Pharmacist, APhA.

Magazine/Trade Publication (Published April (2nd Quarter/Spring) 2002)

Albanese, N. P., & Small, R. E. (2002). Traditional NSAIDs prohibited in Aspirin Sensitive Asthmatic Patients: Can COX-2 inhibitors be used?. Rx Consultant.

Abstract (In Preparation; Not Yet Submitted September 2006)

Coe, H. V., & Albanese, N. P. (2006). Clinical Outcomes Based on Pharmacist Recommendations in a Primary Care Management Setting in High Risk Patients with Diabetes. ASHP Midyear Clinical Meeting; Poster Presented.

Abstract (In Preparation; Not Yet Submitted October (4th Quarter/Autumn) 2005)

Lewis, M., Albanese, N. P., & Notaro, J. C. (2005). Assessment of the Impact of Painful Diabetic Peripheral Neuropathy on Patient Function and Success of Current Pain Management. ASHP Midyear Clinical Meeting; Poster Presented.

Abstract (In Preparation; Not Yet Submitted October (4th Quarter/Autumn) 2005)

Abstract (Working Paper October (4th Quarter/Autumn) 2008)

Mary T. Pasko, PharmD

Research interests are in the area of Infectious Diseases, specifically antimicrobial pharmacotherapeutic issues.

Refereed Journal Articles

Journal Article, Academic Journal (Published September 2007)

Mergenhagen, K. A., & Pasko, M. T. (2007). Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. Ann Pharmacother, 41(9), 1531-1535.

Journal Article, Professional Journal (Submitted June 4, 2009)

Mao, C. l., Rivet, A. J., Sidora, T., & Pasko, M. T. (2009). Update on Pressure Ulcer Management and Deep Tissue Injury. The Annals of Pharmacotherapy.

Gina Prescott, PharmD

Research interests are in the areas women’s health and pharmacy student and resident education/teaching.

Refereed Journal Articles

Journal Article, Professional Journal (Published July (3rd Quarter/Summer) 2009)

Slazak, E. M., & Prescott, G. M. (2009). Practice-Based Learning Experience to develop residents as clinical faculty members. American Journal of Health System Pharmacy.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2008)

Pretorius, R., & Prescott, G. M. (2008). A Systematic Approach to Identifying Drug-Seeking Patients. Family Practice Management, 15(4), A3-A5.

William A. Prescott Jr., PharmD

Research interest include:

Clinical pharmacokinetics and pharmacodynamics of antimicrobials in pediatric patients, with an emphasis in pediatric pulmonology / cystic fibrosis.
Clinical treatment practices in pediatric pulmonology / cystic fibrosis.
Clinical importance of antimicrobial hypersensitivity and cross-hypersensitivity.

Refereed Journal Articles

Journal Article, Professional Journal (Published September 2008)

Monte, S. V., Prescott, W. A., Johnson, K. K., Lori, K., & Paladino, J. A. (2008). Safety of Ceftriaxone at the Extremes of Age. Expert Opinion on Drug Safety, 7(5), 515-23.

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2007)

Prescott, W. A., & Kusmierski, K. A. (2007). Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy, 27(1), 137-42.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2005)

Prescott, W. A., & Johnson, C. E. (2005). Antiinflammatory therapies for cystic fibrosis: past, present, and future.. Pharmacotherapy, 25(4), 555-73.

Journal Article, Professional Journal (Published December 2004)

Prescott, W. A., Streetman, D. A., & Streetman, D. S. (2004). The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.. Annals of Pharmacotherapy, 38(12), 2105-14.

Journal Article, Professional Journal (Published November 2004)

Prescott, W. A., & Btaiche, I. F. (2004). Sincalide in patients with parenteral nutrition-associated gallbladder disease.. Annals of Pharmacotherapy, 38(11), 1942-5.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2004)

Prescott, W. A., DePestel, D. D., Ellis, J. J., & Regal, R. E. (2004). Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy.. Clinical Infectious Diseases, 38(8), 1102-7.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2004)

Prescott, W. A., Callahan, B. L., & Park, J. M. (2004). Tacrolimus toxicity associated with concomitant metoclopramide therapy.. Pharmacotherapy, 24(4), 532-7.

Journal Article, Professional Journal (Published July (3rd Quarter/Summer) 2003)

Prescott, W. A., & Regal, R. E. (2003). Pressure ulcers: What to think when giving zinc.. Pharmacy & Therapeutics, 28(7), 473-4.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Accepted May 10, 2009)

Brazeau, G. A., Meyer, S., Belsey, M., Bednarczyk, E. M., Bilic, S., Bullock, J., DeLander, G., Fiese, E. F., Giroux, S. L., McNatty, D., Nemire, R., Prescott, W. A., & Traynor, A. P. (2009). Future Pharmacy Graduates â€“ Making More Opportunities Than We See. American Journal of Pharmacy Education.

Journal Article, Professional Journal (Revising to Resubmit May 1, 2009)

Prescott, W. A. (2009). Preparing Pharmacy Students for the ASHP Midyear Clinical Meeting and Post-graduate Training Search. American Journal of Health-System Pharmacists.

Journal Article, Professional Journal (Revising to Resubmit May 1, 2009)

Prescott, W. A., & Nagel, J. L. (2009). Safety and Efficacy of Extended Interval Aminoglycoside Dosing in Pediatric and Adult Cystic Fibrosis. Pharmacotherapy.

Journal Article, Professional Journal (In Preparation; Not Yet Submitted May 1, 2009)

Prescott, W. A., Doloresco, F., Brown, J., & Paladino, J. A. (2009). Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review.. PharmacoEconomics.

Other Intellectual Contributions

Study Guide (Published May 2006)

Webster, S., & Prescott, W. A. (2006). Examining the Effects of Parental Alcohol and Drug Abuse on Children.. Center for Development of Human Services.

Newsletter (Published August 2002)

Prescott, W. A. (2002). Methadone: An underused pain medication. (7th ed., vol. 21, pp. 4). The MSHP Monitor.

Alfred Reiman, BS, R.Ph.

Research interests include design of new and innovative drug delivery systems. Current projects include the development of an automated (robotic) filling, metering and dispensing system for transdermal gels.

Practice specialty is the academic side pharmaceutical compounding and institutional dispensing, mentoring students who have career goal interests in academia. These students research, prepare and present lecture materials to the P2-4 classes in Professional Practice (PHM 531/532 LAB/LEC), Advanced Pharmaceutical Compounding Elective (PHM 540) and Basics of Health Systems Pharmacy Practice (PHM 620D) courses.

Joshua Sawyer, PharmD

Book Chapters

Book, Chapter in Scholarly Book-New (Published October (4th Quarter/Autumn) 2008)

Sawyer, J. R., Acosta, E. P., Morse, E. D. (2008). Raltegravir. In Shafer, R. W., Swindells, S., Singh, N., Sun, H. (Eds.), HIV Clinical Manual.

Other Intellectual Contributions

Abstract (Published December 2008)

Sawyer, J. R., Hsia, Y., Akajagbor, D., & Havard, P. F. (2008). Prevalence of Genotypic Drug Mutations in Among a Cohort of HIV-infected Pregnant Women [Abstract # 257]. Louisville, Kentucky: 2008 Annual Meeting of the American College of Clinical Pharmacy, October 19-22, 2008.

Erin Slazak, PharmD

Program Coordinator of the MedSense Program Research Initiative and is the Director of a PGY 1 Residency in Ambulatory Care.

Research interest areas include:

1. Patient-centered pharmacotherapy management of ambulatory disease states.

2. Effect of pharmacist intervention on health care and economic outcomes.

3. Ambulatory management of type 2 diabetes and the earlier use of insulin in type 2 diabetes.

4. Lipid and blood pressure management in the ambulatory type 2 diabetes population.

Refereed Journal Articles

Journal Article, Professional Journal (Published 2009)

Journal Article, Professional Journal (Published July (3rd Quarter/Summer) 2009)

Slazak, E. M., & Prescott, G. M. (2009). Practice-Based Learning Experience to develop residents as clinical faculty members. American Journal of Health System Pharmacy.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Albanese, N. P., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections. American Journal of Managed Care, 14, 190-196.

Journal Article, Professional Journal (Accepted January (1st Quarter/Winter) 2009)

Slazak, E. M., & Zurick, G. M. (2009). A Practice-Based Learning Experience to Develop Residents as Clinical Faculty Members. Am J Health-Syst Pharm, 66.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Paolini, N. M., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections. Am J Manag Care, 14(4), 190-196.

Journal Article, Professional Journal (Published April (2nd Quarter/Spring) 2008)

Monte, S. V., Paolini, N. M., Slazak, E. M., Schentag, J. J., & Paladino, J. A. (2008). Costs of treating lower respiratory tract infections.. Am J Manag Care, 14(4), 190-6.

Other Intellectual Contributions

Abstract (Published December 2008)

Abstract (Published December 2007)

Abstract (Published October (4th Quarter/Autumn) 2007)

Paladino, J. A., Monte, S. V., Albanese, N. P., Slazak, E. M., & Schentag, J. J. (2007). Costs of Outpatients Lower Respiratory Tract Infection in an Adult Managed Care Population. ICAAC.

Abstract (Published July (3rd Quarter/Summer) 2007)

Zurick, G. M., & Slazak, E. M. (2007). A Practice-Based Learning Experience to Develop Residents as Clinical Faculty Members. AACP Annual Meeting.

Abstract (Published July (3rd Quarter/Summer) 2007)

Abstract (Published April (2nd Quarter/Spring) 2007)

Abstract (Published December 2006)

Monte, S. V., Paolini, N., Slazak, E. M., & Paladino, J. A. (2006). Cost of Outpatient Lower Respiratory Tract Infection in an Adult Primary Care Population. ASHP Midyear Clinical Meeting.

Abstract (Published October (4th Quarter/Autumn) 2005)

Slazak, E. M., Paolini, N. M., Broffman, G., & Morse, E. D. (2005). Evaluation of Patient-Centered Pharmacotherapy Management in a Managed Care Organization. ACCP Annual Meeting.

Abstract (In Preparation; Not Yet Submitted October (4th Quarter/Autumn) 2005)

Kathleen M. Tornatore, PharmD

Research works focuses in the area of Clinical Pharmacokinetic and Pharmacodynamic Research of Immunosuppressive Regimens in Renal Transplantation. This clinical research program has been an ongoing collaborative program with the Division of Nephrology at Erie County Medical Center for over 15 years focusing on the pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressive agents during renal transplantation:

Current and upcoming clinical research endeavors focus upon pharmacokinetics of immunosuppressive drugs in relationship to pharmacodynamics of immunologic markers and targeted pharmacogenomic endpoints in relation to race and gender of the renal transplant recipient. Research projects may provide the student with exposure to a variety of biomedical technologies including LCMSMS, flow cytometry and Q-PCR. These projects provide Pharm.D. students with an opportunity to explore clinical and translational research projects though a clinical research team (i.e. Pharm.D.s, physicians, nurse clinicians, immunologists, geneticists, biostatisticians, etc.) by participation in clinical pharmacology sub-studies in renal transplant patients with the endpoint to provide safe and efficacious immuosuppression (e.g. cyclosporine, prednisone, mycophenolic acid) among different patient groups.

In addition, this funded clinical research program has focused on the pharmacokinetics and dynamics of glucocorticoids with specific emphasis on the impact of the factors of gender, race, acute rejection, time post-transplant, immunologic response and chronic adverse effects in the renal transplant population. This research program has also evaluated the pharmacodynamics of anti-lymphocyte induction agents as well as glucocorticoid pharmacokinetics during various “steroid withdrawal” protocols during a multi-center clinical trial.

Refereed Journal Articles

Journal Article, Academic Journal (Published May 2009)

Zachariah, M., Tornatore-Morse, K. M., & Venuto, R. C. (2009). Kidney Transplantation and pregnancy.. Current Opinion in Organ Transplantation, IN Press.

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2009)

Nainani, N., Singh, N., Damodar, A., Parimoo, N., Ummadi, S., Qazi, Y., Murray, B. M., Tornatore-Morse, K. M., Ciccirella, J., Blessios, G. A., & Venuto, R. C. (2009). Cross Reactive Epitope Group Antibodies in Sensitized Kidneys Transplant recipients was associated with Early Acute Antibody Mediated Rejection. Transplant Immunology(20), 113-117.

Journal Article, Academic Journal (Revising to Resubmit May 2009)

Tornatore-Morse, K. M., Suchada, P., DiFrancesco, R., Wilding, G. E., Dole, K., Leca, N., Gundroo, A., & Venuto, R. C. (2009). Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients.. Brit. J Clin. Pharmacol.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 2007)

DiFrancesco, R., Frerichs, V., Donnelly, J., Hagler, C., Hochreiter, J., & Tornatore-Morse, K. M. (2007). Simultaneous Determination of Cortisol, Dexamethasone, Methylprednisolone, Prednisone, Prednisolone, Mycophenolic Acid and Mycophenolic Acid Glucuronide in Human Plasma Utilizing Liquid Chromatography Tandem Mass Spectrometry.. Journal of Chromatography B(859), 42-51.

Journal Article, Academic Journal (Revising to Resubmit July (3rd Quarter/Summer) 2009)

Tornatore-Morse, K. M., Ciminelli, A. M., Gilliland, K. A., Farooqui, M., Reed, K. A., & Venuto, R. C. (2009). The Influence of Race and Gender on Glucocorticoid Pharmacokinetics and Adverse Effects in Renal Transplant Recipients. Clin J Am Soc Nephrol.

Journal Article, Academic Journal (Revising to Resubmit July (3rd Quarter/Summer) 2009)

Tornatore-Morse, K. M., Brazeau, D. A., Dole, K., Gillis, K. A., Wilding, G. E., Leca, N., Yassa, S., & Venuto, R. C. (2009). The Influence of Race and Gender on Time-Dependent Expression of MDR-1 in Stable Renal Transplant Recipients.. Journal of Pharmacogenomics.

Journal Article, Academic Journal (Revising to Resubmit July (3rd Quarter/Summer) 2009)

Tornatore-Morse, K. M., Dole, K., Gillis, K. A., Wallace, P., Wilding, G. E., Leca, N., Yassa, S., & Venuto, R. C. (2009). Time Dependent Pharmacodynamics of Activated T lymphocytes during Immunosuppressive Therapy (IT). J Clin Pharm.

Journal Article, Academic Journal (Revising to Resubmit April (2nd Quarter/Spring) 2009)

Donnelly, J. M., Vannozzi, S. A., DiFrancesco, R., Venuto, R. C., & Tornatore-Morse, K. M. (2009). Comparison of Cyclosporine Concentrations in Renal Transplant Recipients using Enzyme Multiplied Immunoassay Technique (EMITÂ®), Tandem Liquid Chromatography/Mass Spectrometry (LCMS/MS) and Online Turbulent Flow Chromatography coupled with Tandem Mass Spectrometry (TFC-MS/MS);. J. Pharmaceutical and Biomedical Analysis.

Journal Article, Academic Journal (Submitted July (3rd Quarter/Summer) 2009)

Gillis, K. A., Quazi, Y., Karam, J., Blessios, G. A., Schloen, M., Venuto, R. C., & Tornatore-Morse, K. M. (2009). Serial Pharmacodynamic Responses to Abbreviated Induction with Anti - Thymocyte Globulin in Renal Transplant Recipient.. Clinical Transplantation.

Journal Article, Academic Journal (Working Paper September 2009)

Tornatore-Morse, K. M., Brazeau, D. A., Danison, R., Wilding, G. E., Dole, K., & Venuto, R. C. (2009). MDR1 Expression and Cyclosporine Pharmacokinetics in African American and Caucasian Renal Transplant Recipients.. Clin. Pharmacol. Therapeutics.

Other Intellectual Contributions

Abstract (Published May 31, 2009)

Tornatore-Morse, K. M., Dole, K., DiFrancesco, R., Gillis, K. A., Leca, N., Gundroo, A. A., & Venuto, R. C. (2009). Gender Differences in Cyclosporine Pharmacokinetics in Stable African American and Caucasian Renal Allograft Recipients (ed., vol. 9, pp. 496). Malden, MA: Amer J Transplant.

Abstract (Published March 21, 2009)

Tornatore-Morse, K. M., DiFrancesco, R., Suchada, P., Gundroo, A. A., Minderman, H., O'Loughlin, K., Wilding, G. E., Danison, R., & Venuto, R. C. (2009). Assessment of P-glycoprotein in Peripheral Mononuclear Cells in African American and Caucasian Renal Transplant Recipients During Chronic cyclosporine Therapy (ed., vol. 85, pp. S75). New York , New York: Clin. Pharmacol.Ther.

Abstract (Published March 21, 2009)

Tornatore-Morse, K. M., Suchada, P., Brazeau, D. A., & Venuto, R. C. (2009). Time Dependent Expression of MRP-2 in Periperhal Mononuclear Cells in African American and Caucasian Renal Transplant Recipients (ed., vol. 85, pp. S74). New York, New York: Clin. Pharmacol.Ther.

Abstract (Published February 2009)

Abstract (Published January (1st Quarter/Winter) 2009)

Damodor, A., Bhatnagar, J., Zachariah, M., Tornatore-Morse, K. M., Weber-Shrikant, E., Gundroo, A. A., Panesar, M., & Venuto, R. C. (2009). Aggressive Immunosuppression Benefits Post-transplant Glomerulonephritis (2nd ed., vol. 9, pp. 684). Amer J Transplant.

Abstract (Published January (1st Quarter/Winter) 2009)

Abstract (Published November 2008)

Patel, N., Nainani, N., Murray, B. M., Gundroo, A. A., Blessios, G., Tornatore-Morse, K. M., & Venuto, R. C. (2008). Effect of Steroid Avoidance and Low Dose Calcinuerin-Inhibitor Immunosuppression on Progression of Chronic Allograft Nephropathy (CAN) Assessed by Surveillance Biopsy (vol. 19). J Am Soc Nephrol.

Abstract (Published November 2008)

Abstract (Published January (1st Quarter/Winter) 2008)

Nainani, N., Patel, N., Rahman, M., Tahir, N., Murray, B. M., Gundroo, A. A., Blessios, G., Tornatore-Morse, K. M., & Venuto, R. C. (2008). Effect of Steroid Free Mainatenance Immunosuppression Protocol on Progression of Chronic Allograft Nephropathy (2nd ed., vol. 8). Amer J Transplant.

Abstract (Published January (1st Quarter/Winter) 2008)

Suchada, P., Gundroo, A. A., Donnelly, A., DiFrancesco, R., Hochreiter, J., Venuto, R. C., & Tornatore-Morse, K. M. (2008). Influence of Cyclosporine Exposure on the Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients (5th ed., vol. 8). Amer J Transplant.

Abstract (Published January (1st Quarter/Winter) 2008)

Suchada, P., Brazeau, D. A., Dole, K., Venuto, R. C., & Tornatore-Morse, K. M. (2008). Quantitative real-time PCR Analysis of MRP-2 Expression in Peripheral Mononuclear Cells (3rd ed., vol. 82). Clin Pharmacol Ther.

Abstract (Published November 2, 2007)

Tornatore-Morse, K. M., Dole, K., Zack, J., DiFrancesco, R., Gillis, K., Leca, N., Gundroo, A. A., & Venuto, R. C. (2007). Cyclosporine Gender Differences with 12 hour Pharmacokinetic Analysis in Stable Renal Allograft Recipients.. J Am Soc Nephrol.

Abstract (Published November 2, 2007)

Singh, N., Nainani, N., Qazi, Y., Murray, B., Gundroo, A. A., Blessios, G., Tornatore-Morse, K. M., & Venuto, R. C. (2007). Outcomes of Alemtuzumab Induction in High Risk Renal Transplant Recipients.. J Am Soc Nephrol.

Abstract (Published July (3rd Quarter/Summer) 2007)

Tornatore-Morse, K. M., Brazeau, D. A., K. D., Gillis, K. A., Lecca, N., Yassa, S., & Venuto, R. C. (2007). Impact of Gender, Race and Time on MDR-1 Gene Expression in Stable Renal Transplant Recipients (2nd ed., vol. 81). Clin. Pharmacol.Ther.

Abstract (Published July (3rd Quarter/Summer) 2007)

Abstract (Published January (1st Quarter/Winter) 2007)

Suchada, P., Dole, K., Zack, J., lecca, N., Gundroo, A. A., Venuto, R. C., & Tornatore-Morse, K. M. (2007). . Influence of Steroid Use and Gender on Mycophenolic Acid Pharmacokinetics Post-Renal Transplant. (2nd ed., vol. 7, pp. 4500). Amer. J. Transplant..

Abstract (Published January (1st Quarter/Winter) 2007)

Suchada, P., Dole, K., Zack, J., Lecca, N., Gundroo, A. A., Venuto, R. C., & Tornatore-Morse, K. M. (2007). Influence of Race and Steroid Use on Mycophenolic Acid Pharamcokinetics Post- Renal Transplant (449th ed., vol. 7). Amer J Transplant.

Abstract (Published January (1st Quarter/Winter) 2007)

Singh, N., Murray, B. M., Qazi, Y., Hassan, M., Khalil, F., Blessios, G., Tornatore-Morse, K. M., & Venuto, R. C. (2007). Maintenance Steriod Free CAmpath-1H Induction Regimen Reduces Metabolic Complications (2nd ed., vol. 7, pp. 522). Amer J Transplant.

Abstract (Published January (1st Quarter/Winter) 2007)

Qazi, Y., Singh, N., Gundroo, A. A., Khalil, F., Hassan, M., Murray, B. M., Blessios, G., Tornatore-Morse, K. M., & Venuto, R. C. (2007). One year Results of Alemtuzumab Induction, Calcineurin Minimization Protocol in Renal Transplant Recipients Monitored by Surveillance Biopsies. (2nd ed., vol. 7, pp. 444). Amer J Transplant.

Manuscript (In Preparation; Not Yet Submitted September 2009)

Tornatore-Morse, K. M., Fountaine, R., Hom, J., DiFrancesco, R., & Venuto, R. C. (2009). Immunodynamics and Biochemical Assessment of Post-Transplant Osteoporosis. Clin Transplant.

Brian Tsuji, PharmD

Research interests involve investigating of mechanisms of resistance in multi drug resistant bacteria and pharmacokinetic/pharmacodynamic modeling of antimicrobials to suppress the emergence of resistance. Dr. Tsuji’s interest in antimicrobial resistance mechanisms involves the utilization of novel in vitro pharmacodynamic models and investigation of bacterial genetic factors which contribute to drug resistance.

Refereed Journal Articles

Journal Article, Academic Journal (Published May 1, 2009)

Begic, D., Tsuji, B. T. (2009). Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. Journal Antimicrobial Chemotherapy, 2009 May;63(5):977-81..

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 1, 2009)

Tsuji, B. T. (2009). Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density.. Diagn Microbiol Infect Dis, Diagn Microbiol Infect Dis. 2009 Apr 1..

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2009)

Journal Article, Academic Journal (Published July (3rd Quarter/Summer) 1, 2008)

Tsuji, B. T. (2008). In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.. Journal Antimicrobial Agents and Chemotherapy.

Journal Article, Academic Journal (Published April (2nd Quarter/Spring) 2008)

Tsuji, B. T., Rhomberg, P. R., Jones, R. N., Rybak, M. J. (2008). Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn Microbiol Infect Dis, 60(4), 441-444.

Journal Article, Academic Journal (Published December 2007)

Yang, J. C., Forrest, A., & Tsuji, B. T. (2007). Optimizing use of quinolones in the critically ill. Semin Respir Crit Care Med, 28(6), 586-595.

Journal Article, Academic Journal (Accepted June 1, 2009)

Guskey, M., & Tsuji, B. T. (2009). The Novel Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin, and Telavancin. Pharmacotherapy.

Journal Article, Academic Journal (Accepted June 1, 2009)

Harigaya, Y., & Tsuji, B. T. (2009). Vancomcyin Pharmacodynamics at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother.

Journal Article, Academic Journal (Accepted June 1, 2009)

Wu, M., & Tsuji, B. T. (2009). Vancomycin and Daptomycin Pharmacodynamics Differ Against a Site-Directed Staphylococcus epidermidis Mutant Displaying the Small Colony Variant Phenotype. Antimicrob Agents Chemother.

Other Intellectual Contributions

Abstract (Published October (4th Quarter/Autumn) 2008)

McClain, R., Tsuji, B. T. (2008). Canadian Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus (MRSA): An Evaluation of Accessory Gene Regulator (agr) Function and Vancomycin (V) Pharmacodynamics. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy October 25 - 28, 2008, Washington, DC.

Abstract (Published October (4th Quarter/Autumn) 2008)

Begic, D., & Tsuji, B. T. (2008). Comparative Daptomycin (DAP) and Vancomycin (VAN) Activity Against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant (SCV) Phenotype in an In Vitro Pharmacodynamic Model (IVPM). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy October 25 - 28, 2008, Washington, DC.

Abstract (Published October (4th Quarter/Autumn) 2008)

Bulitta, J., & Tsuji, B. T. (2008). Inverse Inoculum Effect of Ciprofloxacin (CIP) and Imipenem (IMI) Against Pseudomonas aeruginosa (Pa) Characterized by New Mechanism-Based Pharmacodynamic (PD) Models. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy October 25 - 28, 2008, Washington, DC.

Abstract (Published October (4th Quarter/Autumn) 2008)

Ly, N., & Tsuji, B. T. (2008). Mechanism-Based Pharmacokinetic / Pharmacodynamic Model for the Inverse Inoculum Effect of Imipenem against Pseudomonas aeruginosa. 2008 AAPS Annual Meeting, Atlanta, GA, USA; November 16 - 20, 2008..

Abstract (Published October (4th Quarter/Autumn) 2008)

Takata, T., & Tsuji, B. T. (2008). Relationship Between Accessory Gene Regulator Locus with Vancomycin Bactericidal Activity and Efficacy in Methicillin-Resistant Staphylococcus aureus Bacteremia. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy October 25 - 28, 2008, Washington, DC.

Abstract (Published October (4th Quarter/Autumn) 2008)

Wu, M., & Tsuji, B. T. (2008). Vancomycin and Daptomycin Pharmacodynamics Differ Against a Site-Directed Staphylococcus epidermidis Mutant Displaying the Small Colony Variant Phenotype. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy October 25 - 28, 2008, Washington, DC.

Robert Wahler, PharmD

Research interests focus on the care of Hospice and Palliative Care patients. This includes investigating the impact of Clinical Pharmacy Services (CPS) on the care of patients as well on the pharmacoeconomic impact on the providers and payors. Specifically, clinical investigations include approaches to opioid use and pain management strategies and use of novel products and delivery systems in patients experiencing nausea and vomiting.

Refereed Journal Articles

Journal Article, Academic Journal (Published November 25, 2005)

Singh, R., Naughton, B., Taylor, J. S., Koenigsberg, M. R., Anderson, D. R., McCausland, L. L., Wahler, R. G., Robinson, A., & Singh, G. (2005). A comprehensive collaborative patient safety residency curriculum to address the ACGME core competencies. MEDICAL EDUCATION, 39(12), 1195-1204.

Other Intellectual Contributions

Abstract (Published July (3rd Quarter/Summer) 2007)

Albanese, N. P., & Wahler, R. G. (2007). Practical Application of the CAPE Educational Outcomes within the Pharmaceutical Care Course Sequence at the University at Buffalo. AACP.

Abstract (Published April (2nd Quarter/Spring) 2006)

Mark Wrobel, PharmD

Other Intellectual Contributions

Abstract (Published April (2nd Quarter/Spring) 2007)

Angela Wisniewski, PharmD

Research interest focuses on: asthma and geriatrics. Current projects include:

Analysis of quantitative information collected on demographic, socioeconomic, and asthma-related variables to identify factors associated with low adherence to asthma medications among predominantly African American and Puerto Rican patients at primary care clinics in Buffalo.
Pharmacist site-investigator for the NHLBI-funded CAPTION (Collaboration Among Pharmacists and Physicians to Improve Outcomes Now) Study which aims to determine if Physician-Pharmacist Collaborative Management (PPCM) of hypertension and asthma can improve blood pressure and asthma control compared to usual care.
Regional study coordinator for the NHLBI-funded "Implementation of NHLBI Asthma Guidelines in Primary Care: A Comparison of 4 Approaches" study which aims to determine if practice facilitation, local learning collaboratives, or both improve care for asthma patients compared to usual care.
Outcomes ascertainment for the AHRQ-funded "A Systems Engineering Approach: Improving Medication Safety with Clinician Use of Health IT" study which aims to determine if an IT-based CRM tool can reduce preventable medication adverse events among ambulatory geriatric patients.

Refereed Journal Articles

Journal Article, Professional Journal (Published June 2009)

Singh, R., McLean-Plunkett, E. A., Kee, R., Bosinski, A., Cadzow, R. B., Okazaki, S., Fox, C. H., & Singh, G. (2009). Experience with a Trigger Tool for Identifying Adverse Drug Events Among Older Adults in Ambulatory Primary Care. Quality and Safety in Health Care, 18(3), 199-204.

Journal Article, Professional Journal (Published January (1st Quarter/Winter) 2008)

Bosinski, A., Purdy, C. H., & Blondell, R. (2008). The Epidemiologic Association Between Opioid Prescribing, Non-medical Use, and Emergency Department Visits. Journal of Addictive Diseases, 27(1), 1-11.

Journal Article, Professional Journal (Published March 2007)

Bosinski, A., Erdley, W. S., Singh, R., Servoss, T. J., Naughton, B., & Singh, G. (2007). Assessment of Safety Attitudes in a Skilled Nursing Facility. Geriatric Nursing, 28(2), 126-136.

Journal Article, Academic Journal (Accepted July (3rd Quarter/Summer) 20, 2009)

Naughton, B., Singh, R., Bosinski, A., Singh, G., & Anderson, D. R. (2009). Improving Quality of NSAID Prescribing by Internal Medicine Trainees with an Educational Intervention. Teaching and Learning in Medicine.

Journal Article, Professional Journal (Accepted June 23, 2009)

Bosinski, A., Naughton, B. (2009). Cross-sectional Survey of Sub-optimal Prescribing in Community Dwelling Older Adults. Journal of the American Geriatrics Society.

Journal Article, Professional Journal (Accepted April (2nd Quarter/Spring) 20, 2009)

Bosinski, A., Zayas, L. E., & Naughton, B. (2009). Primary Care Providers' Assessment of Older Latino Patients' Instrumental Activities of Daily Living: Implications for Improving Quality of Care. Journal of the American Geriatrics Society.

Journal Article, Professional Journal (Not Accepted June 12, 2008)

Fox, C. H., Bosinski, A., & Smith, S. J. (2008). A Pilot Randomized Controlled Trial of Magnesium Supplementation in African Americans with Hypertension. Southern Medical Journal.

Journal Article, Professional Journal (Not Accepted February 18, 2008)

Bosinski, A., Erdley, W. S., Singh, R., Servoss, T. J., & Singh, G. (2008). Prioritizing Medication Safety Vulnerabilities in a Skilled Nursing Facility. Geriatric Nursing.

Journal Article, Professional Journal (Submitted July (3rd Quarter/Summer) 15, 2009)

Zayas, L. E., Bosinski, A., Cadzow, R. B., & Tumiel-Berhalter, L. M. (2009). Knowledge and Use of Ethnomedical Treatments for Asthma Among Puerto Rican Families in a Low-Income Urban Community. Journal of Alternative and Complementary Medicine.

Non-Refereed Journal Articles

Journal Article, Professional Journal (In Preparation; Not Yet Submitted May 28, 2009)

Bosinski, A., Luczkiewicz, D. L., Servoss, T. J., Bisantz, A. M., Singh, R., Singh, G., Naughton, B. (2009). Order Fulfillment Errors Among Ambulatory Older Adults. Journal of the American Geriatrics Society.

Other Intellectual Contributions

Journal article in an edited volume (Published August 2008)

Singh, G., Singh, R., Thomas, E. J., Fish, R., Kee, R. L., McLean-Plunkett, E., Bosinski, A., Okazaki, S., & Anderson, D. R. (2008). Measuring Safety Climate in Primary Care Offices (vol. 2, pp. 14). Rockville, MD: Advances in Patient Safety: New Directions and Alternative Approaches. Volume 2. Culture and Redesign.

Abstract (Published May 2006)

Written Case with Instructional Material (Published August 2004)

Bosinski, A., Nguyen, T. N., & Newberger, D. S. (2004). Sometimes Less is Better: A Case Study on the Treatment of Venous Thromboembolism. National Center for Case Study Teaching in Science.

Department of Pharmaceutical Sciences

Joseph P. Balthasar, PhD

Director, Center for Protein Therapeutics with research focusing on the utilization of pharmacokinetic and pharmacodynamic analyses and mathematical modeling to guide the discovery and development of new immunotherapies for cancer and autoimmunity.

Research Interests and Projects:

1. Development of new therapies for immune thrombocytopenia (ITP). This laboratory has developed new animal models ITP, and these models now allow systematic, mechanistic investigation of new therapies for this common autoimmune disease. Current research is investigating the therapeutic utility of: (a) “Opsisomes” (antibody-coated liposomes) that are designed to block pathways of platelet destruction inITP, (b) an extracorporeal bioreactor that is designed to remove pathogenic autoantibodies, and (c) “Macro-block” a new therapy that is designed to utilize endogenous antibodies and a triggering agent to form immune complexes that block the phagocytic activity of macrophages.

2. Development of FcRn inhibitors. This project focuses on the design and evaluation of inhibitors of FcRn, a transport protein that protects IgG from intracellular catabolism. The inhibitors may have broad utility in the treatment of antibody mediated auto- and allo- immune conditions.

3. Targeting tissue plasminogen activator (tPA). This project will be performed in collaboration with Dr. Victor Yang at the University of Michigan. Research conducted at UB will investigate the utility of novel delivery strategies for selective alteration in the pharmacokinetics and pharmacodynamics of tPA.

4. Targeting chemotherapy with novel derivatives of the TAT peptide. This project represents another collaborative effort between UB and Dr. Yang’s group at the University of Michigan. Research conducted at UB will investigate the utility of novel delivery strategies that attempt to enhance the pharmacokinetic, pharmacodynamic, and therapeutic selectivity of anti-cancer drugs.

5. Inverse targeting for ovarian cancer. This project employs anti-drug antibodies to alter the distribution and elimination kinetics of chemotherapeutics as a means to provide targeted drug therapy of peritoneal metastases of ovarian cancer. Our approach combines intraperitoneal administration of antineoplastic agents with systemic administration of anti-drug antibodies. The presence of anti-drug antibodies in the systemic circulation leads to rapid binding of drug diffusing out of the peritoneum and entering the blood, thereby reducing the extravascular distribution of the chemotherapeutic. It is anticipated that resultant alterations in the pharmacokinetics of the chemotherapeutic will lead to a reduction in the fraction of drug delivered to tissues associated with toxicity (e.g., bone marrow), without affecting peritoneal drug exposure or peritoneal cytotoxic activity. Thus, this drug targeting approach may beneficially alter the efficacy v. toxicity profile of antineoplastics utilized in the treatment of ovarian cancers.

Sathyamangalam Balu-Iyer, PhD

Research interest is in the area of pharmaceutical biotechnology, in particular lipid nano/microparticulate mediated delivery of biotechnology derived products such as therapeutic proteins and siRNA.

Current research projects:

(1) Development of lipidic nano particle containing therapeutic proteins and is supported by NHLBI/NIH. The overall goal of the project is to develop less immunogenic and long acting therapeutic proteins to improve safety and efficacy of protein based products. We adopt multidisciplinary approach involving Biophysics, immunology and pharmacokinetics/Pharmacodynamics.

(2) Re-activating Memory T Cells in the Microenvironment of Human Tumors and development of in situ vaccination. This project is supported by NCI/NIH ((Dr. Bankert, PI, Balu-Iyer Co-PI). Our aim is to develop lipidic Microparticulates containing therapeutics such as IL-12 that can reverse TCR arrest using Biophysical, immunological and Toxico kinetics approaches.

(3) Design lipid based particle to overcome three distinct barriers in si RNA delivery that include (a) Improve in vivo stability; (b) Target organs and cell type and (c) Facilitate intracellular delivery.

(4) Formulation and delivery of Monoclonal antibody based products: We adopt rational strategies based on protein folding approaches to develop stable and efficacious formulations for monoclonal antibody based products.

Javier Blanco, PhD

Research focus is the improvement of cancer chemotherapy by understanding the factors that contribute to interindividual variability in drug response. Dr. Blanco’s goal is to perform translational research using a combination of approaches based on a) the analysis of biological samples from selected populations, and b) the use of informative laboratory models.

A project in Dr. Blanco’s laboratory is related to the understanding of the factors that govern interindividual variability in the metabolism and disposition of the anthracyclines doxorubicin and daunorubicin. It is possible that specific sequence variations in genes associated with the metabolism and disposition of anthracyclines may impact the risk of cardiotoxicity in some individuals. Our efforts are focused on the discovery and characterization of novel single-nucleotide polymorphisms in a family of genes involved in the metabolism of anthracyclines in liver, heart and different types of tumors (e.g. breast and lung cancer). We are investigating the extent of DNA sequence variation in these selected gene candidates among normal individuals from different ethnic groups. We will study genotype-phenotype correlations by using paired tissue-DNA-RNA samples available from my collaborators from the Pharmacogenetics of Anticancer Agents Research group (PAAR, http://www.pharmacogenetics.org/), and from the Roswell Park Cancer Institute (RPCI, http://www.roswellpark.org/document_9.html). We will expand our studies to characterize the functional effect of the genetic variants by using different in-vitro and in-vivo models (e.g. cultures of hepatocytes, cardiomyocytes, transgenic mice).

Our findings are being translated into informative case-control epidemiological studies. I am a co-investigator in the project entitled “Cardiac events among survivors of childhood and adolescent cancer – Role of gene-environment interactions” (PI: Smita Bhatia, City of Hope National Medical Center, CA). The project is sponsored by the Childhood Cancer Survivor Study Group (The Children’s Oncology Group http://www.childrensoncologygroup.org/), and supported by a grant from the Lance Armstrong Foundation. We are analyzing the distribution of the candidate polymorphisms in identically treated patients who have vs. have not developed congestive heart failure (CHF) after anthracycline treatment for childhood cancer. In the future, individualizing the dosing of anthracyclines based on genetic characteristics might minimize the occurrence of adverse effects.

Kathleen MK Boje, PhD

Research interests include:

Neuroinflammatory Brain Diseases. Understanding the role of neuroinflammatory processes in the progression of chronic neurodegenerative diseases. Since inflammatory processes are a common feature of many neurological diseases (viz., Alzheimer's disease, multiple sclerosis, HIV-1 dementia, cerebral ischemia, brain tumors and meningitis), an enhanced knowledge of inflammatory mediators and their detrimental effects on the central nervous system provides opportunities for the design of new pharmaceutical approaches in the management of neurological diseases.
Drug transport across the blood-brain barrier. Focuses on the mechanisms of drug transport across the blood-brain and blood-cerebrospinal fluid barriers. Nature designed these barriers to restrict and regulate the entry of blood borne substances into brain tissue. Essential nutrients are transported efficiently by carrier proteins expressed by the blood-brain and blood-cerebrospinal fluid barriers. However, these barriers hinder the entry of many drugs, and typically it is only highly lipophilic drugs that gain access to brain tissue via passive diffusion across the barriers. Consequently, many lead drug candidates are disqualified from further development because of poor permeability across the blood-brain barrier. There is much scientific interest in understanding brain transport processes with the goal of identifying methods, which enhance drug delivery across brain barriers.
N-Methyl-D-Aspartate Receptors. Explore the pharmacologic modulation of the functional activity and expression of brain N-methyl-D-aspartate receptors (NMDA). The NMDA receptor system is an important glutamate receptor subtype within the central nervous system. Appropriate receptor activation is critical for neuronal development and differentiation, synaptic plasticity, learning and memory processes, whereas receptor over activation initiates or contributes to neurotoxicity and neurodegenerative diseases. Hence, an understanding of the neuropharmacology of NMDA receptors may lead to the development of new drugs for disease management.

Daniel A. Brazeau, PhD

Director, Pharmaceutical Genetics Laboratory (PGL). The roll of the PGL is to provide extensive training and research support for a wide array of molecular genetic techniques to assist researchers in addressing a broad range of questions including gene expression, bioinformatics and genotyping. Students are encouraged to visit the PGL if they are interested in research opportunities in pharmacogenomics or pharmacogenetics. The laboratory has the necessary equipment and expertise to conduct a broad spectrum of techniques in molecular genetic biology including gene expression studies (mRNA Differential Display, northern analysis, microarrays, quantitative real-time PCR) and genotyping (RFLP’s, AFLP’s, ISSR’s, and SNP’s). In addition the PGL provides extensive education and training to not only university students and faculty, but also to outside researchers and professionals through a series of workshops and short courses in DNA microarray technology, statistical packages/programs for genetic analysis, microsatellite development and analysis, and molecular genetic methodologies for the pharmaceutical sciences.

To aid students and faculty in their research the PGL has all the necessary equipment for the isolation, characterization and cloning of DNA/cDNA(mRNA) including three PCR thermocyclers and a Nanodrop ND-1000 Spectrophotometer for measuring DNA/RNA concentrations in small volumes (1 µl). For gene expression studies the laboratory has a separate room (165 sq ft), certified for isotope use with hybridization chambers, incubators, water baths, refrigerator, and centrifuge. The laboratory has a new Kodak large-format image analysis system (Kodak 2000MM Multimodal Imaging System). For scanning of microarray slides the lab has a GenePix 4000A (Axon Instruments). The lab also has an Mx3005P multiplex quantitative PCR system (Stratagene) for gene expression studies and high-throughput genotyping. The laboratory also has a Zeiss Axiovert 220 inverted microscope with DIC and fluorescent capabilities

Gayle A. Brazeau, PhD

Research focuses on investigating the interactions of drugs, molecules and diseases with skeletal muscle from a perspective of characterizing and understanding the mechanisms responsible for tissue damage and/or pain. There are three types of projects that are being investigated in the laboratory. In one area, we have been investigating the mechanisms of tissue damage and/or pain associated with components in parenteral formulations. This work is conducted using a variety of experimental techniques ranging from cell culture to isolated tissues to whole animal studies. In related studies, we have been involved with the development of in situ formulations that cause minimal tissue damage and can provide long-term drug delivery. A second area is focusing on elucidating the mechanisms responsible for pain upon injection. The overall goal is to investigate the link between tissue damage with pain upon injection and to develop excipients or drugs that minimize or eliminate pain or tissue damage upon injection.

We have now investigating the role of myostatin in muscle wasting conditions. A second major focus is to investigate the underlying mechanisms responsible for alcoholic myopathy. Alcoholic myopathy and/or cardiomyopathy is known to occur in 1/3 to 2/3 of those who ingest alcohol on a chronic basis. An understanding of these mechanisms can be used as a basis to develop therapeutic approaches to minimize these toxic effects in cardiac or skeletal muscle. We are also investigating the mechanisms associated with increased susceptibility to muscle and cardiac damage and decreased muscle performance associated with reduced estrogen levels seen in young women, post-menopausal women and in aging. These studies have shown beneficial effects of estrogen, but the mechanisms, either a membrane or receptor mediated, are not clearly elucidated. Alcoholic myopathy and the potential beneficial effects of estrogen on muscle are investigated using our available animal models. In more recent studies, we have been investigating the role myostatin may play as a mediator for muscle growth and/or wasting.

Book Chapters

Book, Chapter in Scholarly Book-New (Published November 2008)

Brazeau, G. A., Anderson, W. K. (2008). Understanding Tenure and Promotion Guidelines and the Role of Faculty Unions. In Chase, P. A., Hayes, B. E., Yanchick, V. A. (Eds.), The Deanâ€™s Compass (vol. Chapter 12, pp. 103-109). Alexxandria, VA: American Association of Colleges of Pharmacy.

Refereed Journal Articles

Journal Article, Academic Journal (Published February 2, 2009)

Brazeau, D. A., Brazeau, G. A. (2009). Role of the Genomics Revolution in Pharmaceutics. Laboratory Medicine, 40(5), 261-266.

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2009)

Wasan, K., Brazeau, G. A., & Fielding, D. (2009). Introduction to the International Pharmacy Education Supplement. American Journal of Pharmaceutical Education(72(6)), Article: 126..

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2008)

Brazeau, D. A., Brazeau, G. A. (2008). Pharmacogenomics of Warfarin Therapy for venous thromboembolism.. Clinical Laboratory(CL-8), 2-5.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published January (1st Quarter/Winter) 2009)

Renzi, S. E., Sauberan, M. E., Brazeau, D. A., & Brazeau, G. A. (2009). Leadership Activities among Students with Varying Pre-Pharmacy Years in College. American Journal of Pharmaceutical Education, 72(6), Article 149.

Journal Article, Academic Journal (Published June 2008)

Kranz, H., Yilmaz, E., Bodmeier, R., & Brazeau, G. A. (2008). In vitro and in vivo drug release from a novel in situ forming drug delivery system. Pharm Res, 25(6), 1347-1354.

Journal Article, Academic Journal (Published June 2008)

Dipiro, J. T., Fincham, J. E., Boucher, B. A., Tracy, T. S., & Brazeau, G. A. (2008). Your role and responsibilities in the manuscript peer review process. Am J Pharm Educ, 72(3), 69.

Journal Article, Academic Journal (Published May 2008)

Rungseevijitprapa, W., Brazeau, G. A., Simkins, J. W., & Bodmeier, R. (2008). Myotoxicity studies of O/W-in situ forming microparticle systems. Eur J Pharm Biopharm, 69(1), 126-133.

Journal Article, Academic Journal (Published October (4th Quarter/Autumn) 2007)

Smesny, A. L., Williams, J. S., Weber, R. J., Matthews, H. W., Das, S. K., & Brazeau, G. A. (2007). Barriers to scholarship in dentistry, medicine, nursing, and pharmacy practice faculty. Am J Pharm Educ, 71(5), 91.

Journal Article, Academic Journal (Accepted October (4th Quarter/Autumn) 2009)

Buring, S. M., Bhushan, A., Brazeau, G. A., Conway, S., Hansen, L., & Westburg, S. (2009). Keys to Successful Implementation of Interprofessional Education: Learning Locations, Facility Development and Curricular Themes. American Journal of Pharmaceutical Education.

Journal Article, Academic Journal (Accepted May 10, 2009)

Other Intellectual Contributions

Abstract (Published July (3rd Quarter/Summer) 2008)

Editorial (Published June 2008)

Brazeau, G. A. (2008). Leadership and learning (3rd ed., vol. 72, pp. 56). Am J Pharm Educ.

Abstract (Published May 2007)

Fiebelkorn, K. D., Grace, P., Renzi, S., Brazeau, G. A. (2007). Correlation of Key Issues Utilizing Curricular Mapping with Outcomes Surveys and Senior Exit Interviews (3rd ed., vol. 71). AJPE.

Abstract (Published May 2006)

Abstract (Published January (1st Quarter/Winter) 2002)

Brazeau, G. A., Haas, C., Fung, H., Fiebelkorn, K. D. (2002). Cultivating Future Clinical and Pharmaceutical Academic Research Leaders in PharmD Students (ed., vol. 66). AJPE.

Abstract (Published July (3rd Quarter/Summer) 1998)

Brazeau, G. A., Haas, C., Fung, H., Fiebelkorn, K. D. (1998). Preparing Students in Professional Practice Lab for the Professional Experience Program (4th ed., vol. 62). AJPE.

Ho-Leung Fung, PhD

Research focuses in the PK/PD of nitric oxide donors and nitric oxide synthase inhibitors, with particular concern regarding mechanisms of tolerance. Dr. Fung is specifically characterizing genetic causes of the development of tolerance to organic nitrates and seeks methods of maximizing the formulation stability and delivery of organic nitrates for treatment of various cardiovascular disorders.

Wenqing Gao, PhD

Research interests include nuclear receptor biology and drug metabolism, with focus on the on the structural biology and molecular mechanism of actions of nuclear receptors and coregulators, molecular pharmacology of selective nuclear receptor modulators, and nuclear receptor-mediated xenobiotic response in drug metabolism.

William J. Jusko, PhD

Research interests are in theoretical, basic, and clinical aspects of the pharmacokinetics and pharmacodynamics of various immunosuppressive agents including corticosteroids, as well as drugs used to treat diabetes, inflammation, and cancer. With Drs. Richard Almon and Debra DuBois, Dr. Jusko delves into the pharmacogenomics of diverse effects of corticosteroids and has evolved advanced mathematical models of receptor/gene-mediated responses. They have characterized the effects of corticosteroids on hepatic and muscle enzymes and tissue responses and have evolved advanced PK/PD models for cascade-type processes. Dr. Jusko has developed mechanism-based pharmacokinetic, pharmacodynamic, and disease progression models and computational methods describing the action of various drugs and utilizes mathematical models of drug action to determine optimal dosage regimens diverse drugs.

Wojciech Krzyzanski, PhD

Research interest focuses on the application of mathematical modeling as a tool to explore functioning of complex biological systems regulated by processes that can be controlled pharmacologically. Dr. Kryzanski’s primary interest is in the hematopoietic system, attempting to reach a balance between his theoretical work in the broadly understood field of pharmacometrics and experimental studies.

Hematopoietic system: Therapeutic applications of hematopoietic growth factors (erythropoietin, thrombopoietin, and G-CSF) and their recombinant human analogs. Toxic effects of anticancer agents on hematopoietic cells in blood and bone marrow. Dynamics of hematopoietic cell populations. Receptor mediated disposition of hematopoietic growth factors.
Pharmacometrics: Development through mathematical analysis and computer simulations of complex indirect response models, in particular, those which describe cell kinetics driven by lifespan distributions. Application of these models in population PK/PD modeling of agents affecting various cell populations.

Donald E. Mager, PharmD, PhD

Research interest areas:

Integrative and Systems Pharmacology of Anti-Platelet and Anti-Cancer Drugs
Development and experimental validation of quantitative structure-pharmacokinetic/pharmacodynamic (PK/PD) relationships (QSPR) to optimize drug design, development, and therapeutic application of anti-cancer compounds.
Integration of QSPR and mechanistic PD models developed with several drugs to predict in vivo PK/PD profiles of chemically related compounds.
Development of models of pharmacological target-mediated drug disposition and dynamics, and the experimental validation of the primary determinants of PK/PD profiles of drugs that exhibit such phenomena.
Development of non-deterministic models such as neural networks, alone or in combination with traditional adaptive feedback control methods, for individual optimization of complex pharmacotherapeutic regimens.
Incorporation of biomedical signal processing tools into PK/PD models for characterizing the pharmacology of drugs that alter spontaneous variability of signals of the cardiovascular and autonomic nervous systems.

Marilyn E. Morris, PhD

Research interests are focused in the areas of drug transport and pharmacokinetics/pharmacodynamics (PK/PD) of drugs. Current research projects:

Gamma-hydroxybutyric acid (GHB) Toxicokinetics and Toxicodynamics. GHB is a drug of abuse, known as a “club drug”. We are characterizing the mechanisms underlying the toxicokinetics and toxicodynamics of GHB, and evaluating methods to treat overdoses of GHB. For these studies, we are characterizing transport of GHB by Monocarboxylic Acid Transporters (MCTs), transport proteins that determine the absorption, renal clearance, and distribution of GHB throughout the body, including its distribution to the brain, the site of action. Our goal is to devise treatment strategies to treat overdoses of GHB, in order to save lives.
Multidrug Resistance in Breast Cancer. Drug resistance is the main cause for therapeutic failure and death in breast cancer. My laboratory is interested in the discovery of new classes of compounds useful in reversing multidrug resistance (MDR) to cancer chemotherapeutic agents. One of the main causes of MDR in cancers is due to the overexpression of the efflux transport proteins, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Our current studies are evaluating various dietary components, organic isothiocyanates and flavonoids, for their effects on BCRP-mediated transport and on the efficacy and toxicity of chemotherapeutic agents.
Cancer Preventive Agents. We are investigating the effects of dietary flavonoids and organic isothiocyantes on cancer initiation and progression, and the use of these natural products in cancer prevention. We are interested in the changes in gene expression produced by these dietary compounds and how these relate to cancer prevention.
Biliary Excretion and Enterohepatic Cycling of Drugs. Our research focuses on the importance of the ABC transport proteins in the biliary excretion of drugs, the in silico and in vitro methods for the prediction of biliary clearance in humans, and modeling enterohepatic cycling of drugs.

Jun Qu, PhD

Research focus areas: Proteomics and Pharmaceutical Analysis. Major research programs in the proteomic field involve i) high-resolution and large-scale expression profiling of pathological proteomes (e.g. for cardiovascular diseases, colon cancer and infectious diseases) for the discovery of disease/therapeutic biomarkers by gel-free LC/MS methods; ii) Sensitive identification, localization and quantification of post-translational modifications in complex proteomes, with the emphases on arginine methylation and phosphorylation. Novel anti-PTM-peptides capture procedure and alternating collision induced dissociation (CID)/electron transferring dissociation (ETD) are employed to obtain abundant PTM information; iii) targeted quantification of regulatory, marker proteins for clinical study. Dr. Qu’s lab possesses many state-of-the-art LC/MS instruments, including a high resolution/accuracy LTQ/Orbitrap XL with ETD, a highly sensitive TSQ Quantum Ultra EMR triple-quadrupole instrument, two ultra-high pressure nano-LC systems, and several HPLC instruments for pre-fraction and ion chromatography. A number of key analytical advances have been developed by his lab that greatly enhanced the proteomic coverage, sensitivity and throughput for proteomic research. As for the Pharmaceutical Analysis of small-molecule drug/markers, Dr. Qu’s lab is focusing on the ultra-sensitive quantifications of drug, metabolites and endogenous markers (e.g. corticosteroids, di-hydroxyl-vitamin D metabolites, androgens, etc.) using a novel combination of selective enrichment and micro- or nano- LC/MS.

Murali Ramanathan, PhD

Research interests are in the area of treatment of multiple sclerosis (MS), an inflammatory-demyelinating disease of the central nervous system that affects over 1 million patients worldwide. MS is a complex, variable disease that causes physical and cognitive disability and nearly 50% if patients diagnosed with MS are unable to walk after 15 years. The etiology and pathogenesis of MS remains poorly understood. The focus of the research is to identify the molecular mechanisms by which the autoimmunity of MS is translated into neurological damage in the CNS.

Current research focuses on work in the following patient-centered MS projects:

Molecular mechanisms of disease and treatment effects in MS and other demylelinating diseases.
Therapy optimization
Gene expression profiling and proteomics
Mathematical models for pharmacogenomic and signal transduction processes and immunomodulatory protein networks.

Jerome J. Schentag, PharmD

Research interest focuses on the effects of acute and chronic diseases on the PK/PD of antibiotics and cardiovascular agents. These studies are primarily conducted in phase II-IV clinical trials of antibiotics and other therapeutic categories. Dr Schentag’s research organization is dedicated to the conduct of Adaptive Clinical Trials incorporating PK/PD methodology into drug development.

Robert M. Straubinger, PhD

Dr. Straubinger’s research program involves the application of drug carriers for the treatment of infectious diseases and cancer. Current efforts are directed toward improving the therapy of brain tumors (as well as others) by targeting tumor blood vessels. We employ a variety of experimental approaches, including high-resolution magnetic resonance imaging, liquid chromatography/mass spectroscopy, confocal fluorescence microscopy and image analysis, pharmacokinetic/dynamic analysis, and molecular techniques such as quantitative RT-PCR. With these techniques, we examine the effects of treatment upon tumor vascular permeability and drug deposition, the localization of the carrier-delivered drug within the tumor, and the molecular mechanisms involved when tumor blood vessels are attacked during therapy.

Additional interests of the lab that are being pursued actively include understanding the mechanisms of anti-cancer drug action and how they may be modified by changing exposure profile (time vs. concentration). Both genomic and proteomic analysis approaches are utilized in this work.

Aiming Yu, PhD

Research interests lie in the field of drug metabolism and disposition. Dr. Yu’s laboratory is interested in studying the function and regulation of human cytochrome P450 (e.g., CYP2D6 and CYP3A4) drug-metabolizing enzymes and ATP-binding cassette (ABC) membrane transporters (e.g., BCRP/ABCG2 and MRP1/ABCC1), and the consequent effects on pharmacokinetics and drug responses. The ultimate goal is to identify the molecular mechanisms of interindividual variability in response to xenobiotic drugs that supports the discovery and development of new drugs, and contributes to a more rational drug therapy.

Role of small noncoding RNAs in the regulation of drug metabolism and disposition in cancer therapy. Understanding the function of small RNAs in regulation of ABC transporter expression shall provide new insight into multidrug resistance, which may offer clue for the development of novel strategy to combating drug-resistant cancers.
Pharmacogenetics in the metabolism of indolealkylamine agents and drug-drug interactions. Delineation of the genetic and environmental factors that affect indolealkylamine metabolism, pharmacokinetics and drug effects will advance the understanding of risk factors in use of psychoactive indolealkylamine drugs.